

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
25 November 2004 (25.11.2004)

PCT

(10) International Publication Number
WO 2004/101605 A1

(51) International Patent Classification⁷: C07K 5/08, A61K 38/06, A61P 31/14

(74) Agent: OGILVY RENAULT; c/o Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval, Quebec H7S 2G5 (CA).

(21) International Application Number:

PCT/CN2004/000318

(22) International Filing Date: 2 March 2004 (02.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/452,281 5 March 2003 (05.03.2003) US

(71) Applicant (for all designated States except DE, US): BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173, 55216 Ingelheim (DE).

(71) Applicant (for DE only): BOEHRINGER INGELHEIM PHARMA GMBH & CO KG [DE/DE]; Binger Strasse 173, 55216 Ingelheim (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): LLINAS-BRUNET, Montse [CA/CA]; 2100 Cunard Street, Laval, Quebec H7S 2G5 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GII, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CI, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HEPATITIS C INHIBITING COMPOUNDS



(57) Abstract: Compounds of formula (I) wherein B, X, R³, R²¹, R²², R¹ and R^c are defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

WO 2004/101605 A1

HEPATITIS C INHIBITING COMPOUNDS

FIELD OF THE INVENTION

The present invention relates to compounds, processes for their synthesis, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel peptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.

10 BACKGROUND OF THE INVENTION

Hepatitis C virus (HCV) is the major etiological agent of post-transfusion and community-acquired non-A non-B hepatitis worldwide. It is estimated that over 200 million people worldwide are infected by the virus. A high percentage of carriers become chronically infected and many progress to chronic liver disease, so-called **15** chronic hepatitis C. This group is in turn at high risk for serious liver disease such as liver cirrhosis, hepatocellular carcinoma and terminal liver disease leading to death.

20 The mechanism by which HCV establishes viral persistence and causes a high rate of chronic liver disease has not been thoroughly elucidated. It is not known how HCV interacts with and evades the host immune system. In addition, the roles of cellular and humoral immune responses in protection against HCV infection and disease have yet to be established. Immunoglobulins have been reported for prophylaxis of transfusion-associated viral hepatitis, however, the Center for **25** Disease Control does not presently recommend immunoglobulins treatment for this purpose. The lack of an effective protective immune response is hampering the development of a vaccine or adequate post-exposure prophylaxis measures, so in the near-term, hopes are firmly pinned on antiviral interventions.

30 Various clinical studies have been conducted with the goal of identifying pharmaceutical agents capable of effectively treating HCV infection in patients afflicted with chronic hepatitis C. These studies have involved the use of interferon-alpha, alone and in combination with other antiviral agents. Such studies have shown that a substantial number of the participants do not respond to these

therapies, and of those that do respond favorably, a large proportion were found to relapse after termination of treatment.


- Until recently, interferon (IFN) was the only available therapy of proven benefit
- 5 approved in the clinic for patients with chronic hepatitis C. However the sustained response rate is low, and interferon treatment also induces severe side-effects (i.e. retinopathy, thyroiditis, acute pancreatitis, depression) that diminish the quality of life of treated patients. Recently, interferon in combination with ribavirin has been approved for patients non-responsive to IFN alone. However, the side effects
- 10 caused by IFN are not alleviated with this combination therapy. Pegylated forms of interferons such as PEG-Intron® and Pegasys® can apparently partially address these deleterious side-effects but antiviral drugs still remain the avenue of choice for oral treatment of HCV.
- 15 Therefore, a need exists for the development of effective antiviral agents for treatment of HCV infection that overcome the limitations of existing pharmaceutical therapies.

HCV is an enveloped positive strand RNA virus in the Flaviviridae family. The single strand HCV RNA genome is approximately 9500 nucleotides in length and has a single open reading frame (ORF) encoding a single large polyprotein of about 3000 amino acids. In infected cells, this polyprotein is cleaved at multiple sites by cellular and viral proteases to produce the structural and non-structural (NS) proteins. In the case of HCV, the generation of mature nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) is effected by two viral proteases. The first one, as yet poorly characterized, cleaves at the NS2-NS3 junction (henceforth referred to as NS2/3 protease); the second one is a serine protease contained within the N-terminal region of NS3 (NS3 protease) and mediates all the subsequent cleavages downstream of NS3, both in *cis*, at the NS3-NS4A cleavage site, and in *trans*, for the remaining NS4A-NS4B, NS4B-NS5A, NS5A-NS5B sites. The NS4A protein appears to serve multiple functions, acting as a cofactor for the NS3 protease and possibly assisting in the membrane localization of NS3 and other viral replicase components. The complex formation of the NS3 protease with NS4A seems necessary to the processing events, enhancing the proteolytic efficiency at all of the

sites. The NS3 protein also exhibits nucleoside triphosphatase and RNA helicase activities. NS5B is a RNA-dependent RNA polymerase that is involved in the replication of HCV.

- 5 A general strategy for the development of antiviral agents is to inactivate virally encoded enzymes that are essential for the replication of the virus.

In WO 00/09543, compounds of the formula



- 10 wherein a preferred meaning of R² is an unsubstituted or mono- or disubstituted quinolinyl residue as defined therein, are described as hepatitis C viral NS3 protease inhibitors, an enzyme essential for the replication of the hepatitis C virus.


- 15 The present invention provides tripeptide compounds that have improved potency against the HCV NS3 protease. Furthermore, compounds being highly active in cell culture are provided.

- 20 An advantage of one aspect of the present invention resides in the fact that compounds according to this invention specifically inhibit the NS3 protease and do not show significant inhibitory activity against other serine proteases such as human leukocyte elastase (HLE), porcine pancreatic elastase (PPE), or bovine pancreatic chymotrypsin, or cysteine proteases such as human liver cathepsin B (Cat B).

- 25 Furthermore, compounds according to this invention can achieve detectable blood plasma levels in pharmacokinetic experiments.

SUMMARY OF THE INVENTION

Included in the scope of the invention is a racemate, diastereoisomer, or optical isomer of a compound of formula (I):



wherein

B is (C_{1-10}) alkyl, (C_{3-7}) cycloalkyl or (C_{1-4}) alkyl- (C_{3-7}) cycloalkyl,

- 5 a) wherein said cycloalkyl and alkyl-cycloalkyl may be mono-, di- or tri-substituted with (C_{1-3}) alkyl; and
- b) wherein said alkyl, cycloalkyl and alkyl-cycloalkyl may be mono- or di-substituted with substituents selected from hydroxy and $O-(C_{1-4})$ alkyl; and
- c) wherein all said alkyl-groups may be mono-, di- or tri-substituted by halogen; and
- d) wherein in all said cycloalkyl-groups being 5-, 6- or 7-membered, one or two $-CH_2$ -groups not being directly linked to each other may be replaced by $-O-$ such that the O-atom is linked to the group **X** via at least two C-atoms;

15

X is O or NH;

R³ is (C_{2-8}) alkyl, (C_{3-7}) cycloalkyl or (C_{1-3}) alkyl- (C_{3-7}) cycloalkyl, wherein all of said alkyl and cycloalkyl groups may be mono-, di- or tri-substituted with (C_{1-4}) alkyl;

20

R²¹ is H, halogen, -OH, (C_{1-6}) alkyl, (C_{3-6}) cycloalkyl, $-(C_{1-4})$ alkyl- (C_{3-6}) cycloalkyl, (C_{1-6}) alkoxy, $-O-(C_{3-6})$ cycloalkyl, $-O-(C_{1-4})$ alkyl- (C_{3-6}) cycloalkyl or $-N(R^{24})_2$, wherein each **R**²⁴ is independently: H, (C_{1-6}) alkyl, $-(C_{3-6})$ cycloalkyl, or $-(C_{1-4})$ alkyl- (C_{3-6}) cycloalkyl;

25

R²² is $-NR^{N2}COOR^0$ or $-NR^{N2}CONR^{N3}R^{N1}$, wherein

R^0 is selected from (C_{1-8})alkyl, (C_{3-7})cycloalkyl and (C_{1-4})alkyl-(C_{3-7})cycloalkyl, wherein said cycloalkyl and alkyl-cycloalkyl may be mono-, di- or tri-substituted with (C_{1-3})alkyl;

R^{N1} is H or R^0 as defined above; and

5 R^{N2} and R^{N3} are independently selected from H and methyl;

R^1 is ethyl or vinyl;

10 R^C is hydroxy or $NHSO_2R^S$ wherein R^S is (C_{1-6})alkyl, (C_{3-7})cycloalkyl or (C_{1-6})alkyl-(C_{3-7})cycloalkyl, phenyl, naphthyl, pyridinyl, (C_{1-4})alkyl-phenyl, (C_{1-4})alkyl-naphthyl or (C_{1-4})alkyl-pyridinyl; all of which optionally being mono-, di- or tri-substituted with substituents selected from halogen, hydroxy, cyano, (C_{1-4})alkyl, O-(C_{1-6})alkyl, -CO-NH₂, -CO-NH((C_{1-4})alkyl), -CO-N((C_{1-4})alkyl)₂, -NH₂, -NH((C_{1-4})alkyl), -N((C_{1-4})alkyl)₂, wherein (C_{1-4})alkyl and O-(C_{1-6})alkyl are optionally mono-, di- or trisubstituted with halogen; and 15 all of which optionally being monosubstituted with nitro;

or a pharmaceutically acceptable salt or ester thereof.

20 Included within the scope of this invention is a pharmaceutical composition comprising an anti-hepatitis C virally effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, in admixture with at least one pharmaceutically acceptable carrier medium or auxiliary agent.

25 According to a further aspect of this embodiment the pharmaceutical composition according to this invention comprises a therapeutically effective amount of at least one other antiviral agent. This other antiviral agent is preferably selected from another anti-HCV agent, HIV inhibitor, HAV inhibitor and HBV inhibitor.

30 Another important aspect of the invention involves a method of treating or preventing a hepatitis C viral infection in a mammal by administering to the mammal an anti-hepatitis C virally effective amount of a compound of formula I, a pharmaceutically acceptable salt or ester thereof, or a composition as described above, alone or in combination with at least one antiviral agent, administered

together or separately.

- Also within the scope of this invention is the use of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, as described herein, for the
- 5 manufacture of a medicament for the treatment or prevention of hepatitis C viral infection in a mammal.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Definitions


10

As used herein, the following definitions apply unless otherwise noted:

With reference to the instances where (R) or (S) is used to designate the absolute configuration of a substituent or asymmetric center of a compound of formula I, the designation is done in the context of the whole compound and not in the context of
15 the substituent or asymmetric center alone.

The designation "P1, P2, and P3" as used herein refer to the position of the amino acid residues starting from the C-terminus end of the peptide analogs and extending towards the N-terminus (i.e. P1 refers to position 1 from the C-terminus, P2: second
20 position from the C-terminus, etc.) (see Berger A. & Schechter I., Transactions of the Royal Society London series B257, 249-264 (1970)).


As used herein the term "(1R, 2S)-vinyl-ACCA" refers to a compound of formula:



25 namely, (1R, 2S) 1-amino-2-ethenylcyclopropanecarboxylic acid.

The term "(C_{1-n})alkyl" as used herein, either alone or in combination with another substituent, means acyclic, straight or branched chain alkyl substituents containing from 1 to n carbon atoms. "(C₁₋₆)alkyl" includes, but is not limited to, methyl, ethyl, n-propyl, n-butyl, 1-methylethyl (i-propyl), 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl (*tert*-butyl), pentyl and hexyl. The abbreviation Me denotes a methyl group.

- The term "(C₃₋₇)cycloalkyl" as used herein, either alone or in combination with another substituent, means a cycloalkyl substituent containing from 3 to 7 carbon atoms and includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
- 5 The term "(C_{1-n})alkyl-(C₃₋₇)cycloalkyl" as used herein means an alkylene radical containing 1 to n carbon atoms to which a cycloalkyl radical containing from 3 to 7 carbon atoms is directly linked; for example, cyclopropylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl and cycloheptylpropyl.
- 10 The term "C₆ or C₁₀ aryl" as used herein, either alone or in combination with another radical, means either an aromatic monocyclic group containing 6 carbon atoms or an aromatic bicyclic group containing 10 carbon atoms. For example, aryl includes phenyl, 1-naphthyl or 2-naphthyl.
- 15 As used herein, the term "alkyl-aryl" means an alkyl radical to which an aryl is bonded. Examples of (C₁₋₃)alkyl-aryl are benzyl (phenylmethyl), phenylethyl and phenylpropyl.
- 20 The term "O-(C_{1-n})alkyl" or "(C_{1-n})alkoxy" as used herein, either alone or in combination with another radical, means the radical -O-(C_{1-n})alkyl wherein alkyl is as defined above containing up to n carbon atoms, and includes methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy and 1,1-dimethylethoxy. The latter radical is known commonly as *tert*-butoxy.
- 25 The term "halo" as used herein means a halogen substituent selected from fluoro, chloro, bromo or iodo.
- 30 The term "pharmaceutically acceptable ester" as used herein, either alone or in combination with another substituent, means esters of the compound of formula I in which any of the carboxyl functions of the molecule, but preferably the carboxy terminus, is replaced by an alkoxy carbonyl function:



in which the R moiety of the ester is selected from alkyl (e.g. methyl, ethyl, *n*-propyl, *tert*-butyl, *n*-butyl); alkoxyalkyl (e.g. methoxymethyl); alkoxyacetyl (e.g. acetoxyethyl); aralkyl (e.g. benzyl); aryloxyalkyl (e.g. phenoxyethyl); aryl (e.g. phenyl), optionally substituted with halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy. Other suitable prodrug esters can be found in Design of prodrugs, Bundgaard, H. Ed. Elsevier (1985) incorporated herewith by reference. Such pharmaceutically acceptable esters are usually hydrolyzed *in vivo* when injected in a mammal and transformed into the acid form of the compound of formula I.

With regard to the esters described above, unless otherwise specified, any alkyl moiety present advantageously contains 1 to 16 carbon atoms, particularly 1 to 6 carbon atoms. Any aryl moiety present in such esters advantageously comprises a phenyl group.

In particular the esters may be a C₁₋₁₆ alkyl ester, an unsubstituted benzyl ester or a benzyl ester substituted with at least one halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro or trifluoromethyl.

The term "pharmaceutically acceptable salt" means a salt of a compound of formula (I) which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, generally water or oil-soluble or dispersible, and effective for their intended use. The term includes pharmaceutically-acceptable acid addition salts and pharmaceutically-acceptable base addition salts. Lists of suitable salts are found in, e.g., S.M. Birge et al., J. Pharm. Sci., 1977; 66, pp. 1-19, which is hereby incorporated by reference in its entirety.

The term "pharmaceutically-acceptable acid addition salt" means those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, phosphoric acid, and the like, and organic acids such as acetic acid, trifluoroacetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, butyric acid, camphoric acid, camphorsulfonic acid, cinnamic acid, citric acid, digluconic acid, ethanesulfonic acid, glutamic acid, glycolic acid, glycerophosphoric

acid, hemisulfic acid, hexanoic acid, formic acid, fumaric acid, 2-hydroxyethanesulfonic acid (isethionic acid), lactic acid, hydroxymaleic acid, malic acid, malonic acid, mandelic acid, mesitylenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, nicotinic acid, 2-naphthalenesulfonic acid, oxalic acid, 5 pamoic acid, pectinic acid, phenylacetic acid, 3-phenylpropionic acid, pivalic acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, p-toluenesulfonic acid, undecanoic acid, and the like.

The term "pharmaceutically-acceptable base addition salt" means those salts which 10 retain the biological effectiveness and properties of the free acids and which are not biologically or otherwise undesirable, formed with inorganic bases such as ammonia or hydroxide, carbonate, or bicarbonate of ammonium or a metal cation such as sodium, potassium, lithium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Particularly preferred are the ammonium, potassium, 15 sodium, calcium, and magnesium salts. Salts derived from pharmaceutically- acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, quaternary amine compounds, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion-exchange resins, such as methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, isopropylamine, tripropylamine, tributylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, tetramethylammonium compounds, tetraethylammonium 20 compounds, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephénamine, N,N'-dibenzylethylenediamine, polyamine resins, and the like. Particularly preferred organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.

30 The term "mammal" as it is used herein is meant to encompass humans, as well as non-human mammals which are susceptible to infection by hepatitis C virus including domestic animals, such as cows, pigs, horses, dogs and cats, and non-domestic animals.

The term "antiviral agent" as used herein means an agent (compound or biological) that is effective to inhibit the formation and/or replication of a virus in a mammal. This includes agents that interfere with either host or viral mechanisms necessary
5 for the formation and/or replication of a virus in a mammal. Such agents can be selected from: another anti-HCV agent, HIV inhibitor, HAV inhibitor and HBV inhibitor. Antiviral agents include, for example, ribavirin, amantadine, VX-497 (merimepodib, Vertex Pharmaceuticals), VX-498 (Vertex Pharmaceuticals), Levovirin, Viramidine, Ceplene (maxamine), XTL-001 and XTL-002 (XTL
10 Biopharmaceuticals).

The term "other anti-HCV agent" as used herein means those agents that are effective for diminishing or preventing the progression of hepatitis C related symptoms of disease. Such agents can be selected from: immunomodulatory
15 agents, inhibitors of HCV NS3 protease, inhibitors of HCV polymerase or inhibitors of another target in the HCV life cycle.

The term "immunomodulatory agent" as used herein means those agents (compounds or biologicals) that are effective to enhance or potentiate the immune
20 system response in a mammal. Immunomodulatory agents include, for example, class I interferons (such as α -, β -, δ - and ω interferons, τ -interferons, consensus interferons and asialo-interferons), class II interferons (such as γ -interferons) and pegylated interferons.

25 The term "inhibitor of HCV NS3 protease" as used herein means an agent (compound or biological) that is effective to inhibit the function of HCV NS3 protease in a mammal. Inhibitors of HCV NS3 protease include, for example, those compounds described in WO 99/07733, WO 99/07734, WO 00/09558, WO
00/09543, WO 00/59929, WO 03/064416, WO 03/064455, WO 03/064456, WO
30 02/060926, WO 03/053349, WO 03/099316 or WO 03/099274, and the Vertex pre-development candidate identified as VX-950.

The term "inhibitor of HCV polymerase" as used herein means an agent (compound or biological) that is effective to inhibit the function of an HCV polymerase in a

mammal. This includes, for example, inhibitors of HCV NS5B polymerase. Inhibitors of HCV polymerase include non-nucleosides, for example, those compounds described in:

- US Application No. 60/441,674 filed January 22, 2003, herein incorporated by reference in its entirety (Boehringer Ingelheim),
- US Application No. 60/441,871 filed January 22, 2003, herein incorporated by reference in its entirety (Boehringer Ingelheim),
- US Application No. 10/198,680 filed 18 July 2002, herein incorporated by reference in its entirety, which corresponds to WO 03/010140 (Boehringer Ingelheim),
- US Application No. 10/198,384 filed 18 July 2002, herein incorporated by reference in its entirety, which corresponds to WO 03/010141 (Boehringer Ingelheim),
- US Application No. 10/198,259 filed 18 July 2002, herein incorporated by reference in its entirety, which corresponds to WO 03/007945 (Boehringer Ingelheim),
- WO 03/026587 (Bristol Myers Squibb);
- WO 02/100846 A1 and WO 02/100851 A2 (both Shire),
- WO 01/85172 A1 and WO 02/098424 A1 (both GSK),
- WO 00/06529 and WO 02/06246 A1 (both Merck),
- WO 01/47883 and WO 03/000254 (both Japan Tobacco) and
- EP 1 256 628 A2 (Agouron).

Furthermore other inhibitors of HCV polymerase also include nucleoside analogs, for example, those compounds described in:

- WO 01/90121 A2 (Idenix);
- WO 02/069903 A2 (Biocryst Pharmaceuticals Inc.), and
- WO 02/057287 A2 and WO 02/057425 A2 (both Merck/Isis).

Specific examples of inhibitors of an HCV polymerase, include JTK-002/003 and JTK-109 (Japan Tobacco) and NM-283 (Idenix).

30

The term "inhibitor of another target in the HCV life cycle" as used herein means an agent (compound or biological) that is effective to inhibit the formation and/or replication of HCV in a mammal other than by inhibiting the function of the HCV NS3 protease. This includes agents that interfere with either host or HCV viral

mechanisms necessary for the formation and/or replication of HCV in a mammal. Inhibitors of another target in the HCV life cycle include, for example, agents that inhibit a target selected from helicase, NS2/3 protease and internal ribosome entry site (IRES). Specific examples of inhibitors of another target in the HCV life cycle 5 include ISIS-14803 (ISIS Pharmaceuticals).

The term "HIV inhibitor" as used herein means an agent (compound or biological) that is effective to inhibit the formation and/or replication of HIV in a mammal. This includes agents that interfere with either host or viral mechanisms necessary for the 10 formation and/or replication of HIV in a mammal. HIV inhibitors include, for example, nucleoside inhibitors, non-nucleoside inhibitors, protease inhibitors, fusion inhibitors and integrase inhibitors.

The term "HAV inhibitor" as used herein means an agent (compound or biological) 15 that is effective to inhibit the formation and/or replication of HAV in a mammal. This includes agents that interfere with either host or viral mechanisms necessary for the formation and/or replication of HAV in a mammal. HAV inhibitors include Hepatitis A vaccines, for example, Havrix® (GlaxoSmithKline), VAQTA® (Merck) and Avaxim® (Aventis Pasteur).

20 The term "HBV inhibitor" as used herein means an agent (compound or biological) that is effective to inhibit the formation and/or replication of HBV in a mammal. This includes agents that interfere with either host or viral mechanisms necessary for the formation and/or replication of HBV in a mammal. HBV inhibitors include, for 25 example, agents that inhibit HBV viral DNA polymerase or HBV vaccines. Specific examples of HBV inhibitors include Lamivudine (Epivir-HBV®), Adefovir Dipivoxil, Entecavir, FTC (Coviracil®), DAPD (DXG), L-FMAU (Clevudine®), AM365 (Amrad), Ldt (Telbivudine), monoval-LdC (Valtorcitabine), ACH-126,443 (L-Fd4C) (Achillion), MCC478 (Eli Lilly), Racivir (RCV), Fluoro-L and D nucleosides, Robustaflavone, ICN 30 2001-3 (ICN), Bam 205 (Novelos), XTL-001 (XTL), Imino-Sugars (Nonyl-DNJ) (Synergy), HepBzyme; and immunomodulator products such as: interferon alpha 2b, HE2000 (Hollis-Eden), Theradigm (Epimmune), EHT899 (Enzo Biochem), Thymosin alpha-1 (Zadaxin®), HBV DNA vaccine (PowderJect), HBV DNA vaccine (Jefferson Center), HBV antigen (OraGen), BayHep B® (Bayer), Nabi-HB® (Nabi) and

- Anti-hepatitis B (Cangene); and HBV vaccine products such as the following: Engerix B, Recombivax HB, GenHevac B, Hepacare, Bio-Hep B, TwinRix, Comvax, Hexavac.
- 5 The term "class I interferon" as used herein means an interferon selected from a group of interferons that all bind to receptor type I. This includes both naturally and synthetically produced class I interferons. Examples of class I interferons include α , β -, δ -, ω interferons, τ -interferons, consensus interferons, asialo-interferons and pegylated forms thereof.
- 10 The term "class II interferon" as used herein means an interferon selected from a group of interferons that all bind to receptor type II. Examples of class II interferons include γ -interferons.
- 15 Specific preferred examples of some of these agents are listed below:
- antiviral agents: ribavirin and amantadine;
 - immunomodulatory agents: class I interferons, class II interferons and pegylated interferons;
 - HCV polymerase inhibitors: nucleoside analogs and non-nucleosides;
 - 20 ▪ inhibitor of another target in the HCV life cycle that inhibits a target selected from: NS3 helicase, NS2/3 protease or internal ribosome entry site (IRES);
 - HIV inhibitors: nucleosidic inhibitors, non-nucleosidic inhibitors, protease inhibitors, fusion inhibitors and integrase inhibitors; or
 - HBV inhibitors: agents that inhibit viral DNA polymerase or is an HBV vaccine.
- 25 As discussed above, combination therapy is contemplated wherein a compound of formula (1), or a pharmaceutically acceptable salt thereof, is co-administered with at least one additional agent selected from: an antiviral agent, an immunomodulatory agent, another inhibitor of HCV NS3 protease, an inhibitor of HCV polymerase, an inhibitor of another target in the HCV life cycle, an HIV inhibitor, an HAV inhibitor and an HBV inhibitor. Examples of such agents are provided in the Definitions section above. These additional agents may be combined with the compounds of this invention to create a single pharmaceutical dosage form. Alternatively these additional agents may be separately administered to the patient as part of a multiple

dosage form, for example, using a kit. Such additional agents may be administered to the patient prior to, concurrently with, or following the administration of a compound of formula (1), or a pharmaceutically acceptable salt thereof.

- 5 As used herein, the term "treatment" means the administration of a compound or composition according to the present invention to alleviate or eliminate symptoms of the hepatitis C disease and/or to reduce viral load in a patient.

- 10 As used herein, the term "prevention" means the administration of a compound or composition according to the present invention post-exposure of the individual to the virus but before the appearance of symptoms of the disease, and/or prior to the detection of the virus in the blood.

- 15 The following sign --- is used in sub-formulas to indicate the bond, which is connected to the rest of the molecule as defined.

Preferred embodiments

In the following preferred embodiments, groups and substituents of the compounds according to this invention are described in detail.

- 20 **B** is preferably selected from (C₂₋₈)alkyl, (C₃₋₇)cycloalkyl and (C₁₋₃)alkyl-(C₃₋₇)cycloalkyl,
a) wherein said cycloalkyl and alkyl-cycloalkyl may be mono-, di- or tri-substituted with (C₁₋₃)alkyl; and
25 b) wherein all of which may be mono- or di-substituted with hydroxy or O-(C₁₋₄)alkyl; and
c) wherein all said alkyl-groups may be mono-, di- or tri-substituted with fluorine or mono-substituted by chlorine or bromine, and
d) wherein in all said cycloalkyl-groups being 5-, 6- or 7-membered, one or two
30 -CH₂-groups not being directly linked to each other may be replaced by -O- such that the O-atom is linked to the group **X** via at least two C-atoms.

More preferably **B** is selected from ethyl, n-propyl, i-propyl, n-butyl, 1-methylpropyl, 2-methylpropyl, *tert*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,

- cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl,
a) wherein each of said cycloalkyl and alkyl-cycloalkyl groups optionally being
substituted by 1 to 3 substituents selected from methyl and ethyl;
b) wherein each of said groups optionally being mono- or di-substituted with
5 substituents selected from hydroxy, methoxy and ethoxy; and
c) wherein each of said alkyl groups may be mono-, di- or tri-substituted with
fluorine or mono-substituted by chlorine or bromine; and
d) wherein in all said cycloalkyl-groups being 5-, 6- or 7-membered, one or two
-CH₂-groups not being directly linked to each other may be replaced by -O-
10 such that the O-atom is linked to the group X via at least two C-atoms.


B is most preferably selected from ethyl, 1-methylethyl, 1,1-dimethylethyl, propyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1,2,2-trimethylpropyl, 1-ethylpropyl, 1-ethyl-2-methylpropyl, 1-(1-methylethyl)-2-methylpropyl, 1-ethyl-2,2-dimethylpropyl, butyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,2-dimethylbutyl, 1,1-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1,2,2-trimethylbutyl, 1,2,3-trimethylbutyl, 2,2,3-trimethylbutyl, 2,3,3-trimethylbutyl and 2,2,3-trimethylbutyl, whereby these alkyl-groups may be substituted with chlorine or bromine or 1, 2 or 3 fluorine substituents. Examples of preferred fluorinated alkyl groups are 2-fluoroethyl and 3,3,3-trifluoropropyl.

Furthermore most preferably, B is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl; 25 optionally substituted with one or two methyl substituents.

Most preferably B is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-methylcyclopentyl and 1-methylcyclohexyl.


30 Even most preferably B is selected from cyclobutyl, cyclopentyl and cyclohexyl.

In addition, most preferably B is selected from the following formulas, wherein a CH₂-group of a cycloalkyl group is replaced by oxygen:



The above listed cycloalkyl and alkyl-cycloalkyl groups, optionally comprising 1 or 2 O-atoms, are optionally substituted by 1, 2 or 3 methyl-groups. Especially those cycloalkyl groups, optionally comprising 1 or 2 O-atoms, are preferred, wherein the α -C-atom is substituted with methyl.

Examples of preferred substituted cyclic groups are



10 According to one embodiment of this invention X is O.

According to another embodiment of this invention X is NH.

15 R^3 is preferably selected from ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl, all of which optionally being substituted by 1 to 3 substituents selected from methyl, ethyl and propyl.

20 More preferably R^3 is selected from 1-methylethyl, 1,1-dimethylethyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, cyclopentyl, cyclohexyl, 1-methyl-cyclopentyl, 1-methyl-cyclohexyl, cyclopentylmethyl, cyclohexylmethyl, (1-methyl-cyclopentyl)-methyl and (1-methyl-

cyclohexyl)-methyl.

R^3 is most preferably selected from 1,1-dimethylethyl, cyclopentyl, cyclohexyl and 1-methylcyclohexyl.

5

R^3 is even most preferably selected from 1,1-dimethylethyl and cyclohexyl.

The substituent R^{21} is preferably selected from halogen, -OH, (C_{1-3})alkoxy or $N(R^{24})_2$, wherein each R^{24} is independently: H or (C_{1-6})alkyl.

10

More preferably R^{21} is selected from -OH, -OCH₃ and -N(CH₃)₂, wherein -OCH₃ and -N(CH₃)₂ is the most preferred definition. Even most preferably, R^{21} is -OCH₃.

15

The substituent R^{22} is preferably defined as -NHCOOR⁰ or -NHCONHR^{N1}, wherein R^{N1} and R⁰ are defined as hereinbefore or hereinafter. More preferably, R^{22} is defined as -NHCOOR⁰.

20

According to a preferred embodiment R⁰ and R^{N1} are selected from the group consisting of methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, and cyclohexylmethyl, wherein said cycloalkyl and alkyl-cycloalkyl groups are unsubstituted or substituted with 1 to 3 substituents selected from methyl and ethyl.


25

Most preferably herein R⁰ and R^{N1} are independently selected from ethyl, 1-methylethyl and cyclopentyl.

30


In the moiety P1 the substituent R¹ and the carbonyl take a *syn* orientation.

Therefore, in the case R¹ is ethyl, the asymmetric carbon atoms in the cyclopropyl group take the *R,R* configuration according to the subformula:



In the case R^1 is vinyl, the asymmetric carbon atoms in the cyclopropyl group take the *R,S* configuration according to the subformula:

5



R^1 is preferably vinyl.

R^C is preferably selected from hydroxy or $NHSO_2R^S$

- wherein R^S is methyl, ethyl, n-propyl, i-propyl, n-butyl, 1-methylpropyl, 2-methylpropyl, *tert*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, phenyl, naphthyl, pyridinyl, phenylmethyl (benzyl), naphthylmethyl or pyridinylmethyl;
- all of which optionally being mono-, di- or tri-substituted with substituents selected from fluorine and methyl; and
 - all of which optionally being mono- or disubstituted with substituents selected from hydroxy, trifluoromethyl, methoxy and trifluoromethoxy; and
 - all of which optionally being monosubstituted with substituents selected from chlorine, bromine, cyano, nitro, -CO-NH₂, -CO-NHCH₃, -CO-N(CH₃)₂, -NH₂, -NH(CH₃) and -N(CH₃)₂.


20

Most preferably, R^C is hydroxy, $NHSO_2$ -methyl, $NHSO_2$ -ethyl, $NHSO_2$ -(1-methyl)ethyl, $NHSO_2$ -propyl, $NHSO_2$ -cyclopropyl, $NHSO_2$ -cyclopropylmethyl, $NHSO_2$ -cyclobutyl, $NHSO_2$ -cyclopentyl or $NHSO_2$ -phenyl.

25

According to a most preferred embodiment, the group R^C is hydroxy. According to an alternative most preferred embodiment, the group R^C is $NHSO_2$ -cyclopropyl.

According to a preferred embodiment of this invention, compounds are represented by formula:



wherein

- B** is (C₁₋₁₀)alkyl, (C₃₋₇)cycloalkyl or (C₁₋₄)alkyl-(C₃₋₇)cycloalkyl,
 - a) wherein said cycloalkyl and alkyl-cycloalkyl may be mono-, di- or tri-substituted with (C₁₋₃)alkyl; and
 - b) wherein said alkyl, cycloalkyl and alkyl-cycloalkyl may be mono- or di-substituted with substituents selected from hydroxy and O-(C₁₋₄)alkyl; and
 - c) wherein all said alkyl-groups may be mono-, di- or tri-substituted by halogen; and
 - d) wherein in all said cycloalkyl-groups being 5-, 6- or 7-membered, one or two -CH₂-groups not being directly linked to each other may be replaced by -O- such that the O-atom is linked to the group **X** via at least two C-atoms;

15 **X** is O or NH;

- R**³ is (C₂₋₈)alkyl, (C₃₋₇)cycloalkyl or (C₁₋₃)alkyl-(C₃₋₇)cycloalkyl, wherein said cycloalkyl groups may be mono-, di- or tri-substituted with (C₁₋₄)alkyl;
- 20 **R**²¹ H, halogen, -OH, (C₁₋₆)alkyl, (C₃₋₆)cycloalkyl, -(C₁₋₄)alkyl-(C₃₋₆)cycloalkyl, (C₁₋₆)alkoxy, -O-(C₃₋₆)cycloalkyl, -O-(C₁₋₄)alkyl-(C₃₋₆)cycloalkyl or -N(**R**²⁴)₂, wherein each **R**²⁴ is independently: H, (C₁₋₆)alkyl, -(C₃₋₆)cycloalkyl, or -(C₁₋₄)alkyl-(C₃₋₆)cycloalkyl;
- 25 **R**²² is -NR^{N2}COOR⁰ or -NR^{N2}CONR^{N3}R^{N1}, wherein R⁰ is selected from (C₁₋₆)alkyl, (C₃₋₇)cycloalkyl and (C₁₋₄)alkyl-(C₃₋₇)cycloalkyl, wherein said cycloalkyl, alkyl-cycloalkyl may be mono-, di- or tri-substituted

with (C_{1-3})alkyl;

R^{N1} is H or R^0 as defined above; and


R^{N2} and R^{N3} are independently selected from H and methyl;

5 R^1 is ethyl or vinyl;

10 R^C is hydroxy or $NHSO_2R^S$ wherein R^S is (C_{1-6})alkyl, (C_{3-7})cycloalkyl or (C_{1-6})alkyl-(C_{3-7})cycloalkyl, phenyl, naphthyl, pyridinyl, (C_{1-4})alkyl-phenyl, (C_{1-4})alkyl-naphthyl or (C_{1-4})alkyl-pyridinyl; all of which optionally being mono-, di- or tri-substituted with substituents selected from halogen, hydroxy, cyano, (C_{1-4})alkyl, O-(C_{1-6})alkyl, -CO-NH₂, -CO-NH((C_{1-4})alkyl), -CO-N((C_{1-4})alkyl)₂, -NH₂, -NH((C_{1-4})alkyl), -N((C_{1-4})alkyl)₂; and all of which optionally being monosubstituted with nitro;

15 or a pharmaceutically acceptable salt or ester thereof.

According to another preferred embodiment of this invention, compounds are represented by formula:



20 wherein R^{21} is -OCH₃ or N(CH₃)₂;

R^{22} is -NHCOOR⁰ or -NHCONHR^{N1}, wherein

R^0 and R^{N1} is each independently selected from (C_{1-4})alkyl or (C_{3-6})cycloalkyl;

B is (C_{4-6})cycloalkyl;

X is O or NH;

25 R^3 is *tert*-butyl or cyclohexyl;

R^C is hydroxy or $NHSO_2R^S$ wherein R^S is (C_{1-4})alkyl, (C_{3-6})cycloalkyl or phenyl; or a pharmaceutically acceptable salt or ester thereof.

Preferably, R^{21} is -OCH₃; R^{22} is -NHCOOR⁰ wherein R^0 is isopropyl or cyclopentyl;

and R^S is, cyclopropyl.

Also preferably, R^C is hydroxy. More preferably, R^{21} is $-OCH_3$; R^{22} is $-NHCOOR^0$ wherein R^0 is isopropyl or cyclopentyl and R^C is hydroxy.

5

Examples of preferred compounds according to this invention are listed in the following Tables 1 and 2.

According to an alternate embodiment, the pharmaceutical composition of this 10 invention may additionally comprise at least one other anti-HCV agent. Examples of anti-HCV agents include, α - (alpha), β - (beta), δ - (delta), γ - (gamma), ω - (omega) and τ - (tau) interferon, pegylated α -interferon, ribavirin and amantadine.

According to another alternate embodiment, the pharmaceutical composition of this 15 invention may additionally comprise at least one other inhibitor of HCV NS3 protease.

According to another alternate embodiment, the pharmaceutical composition of this 20 invention may additionally comprise at least one inhibitor of HCV polymerase.

According to yet another alternate embodiment, the pharmaceutical composition of this invention may additionally comprise at least one inhibitor of other targets in the HCV life cycle, including but not limited to, helicase, NS2/3 protease or internal 25 ribosome entry site (IRES).

The pharmaceutical composition of this invention may be administered orally, 30 parenterally or via an implanted reservoir. Oral administration or administration by injection is preferred. The pharmaceutical composition of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intra-articular, 35 intrasynovial, intrasternal, intrathecal, and intralesional injection or infusion.

techniques.

- The pharmaceutical composition may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension.
- 5 This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example Tween 80) and suspending agents.

The pharmaceutical composition of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous suspensions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.

Other suitable vehicles or carriers for the above noted formulations and compositions can be found in standard pharmaceutical texts, e.g. in "Remington's Pharmaceutical Sciences", The Science and Practice of Pharmacy, 19th Ed. Mack Publishing Company, Easton, Penn., (1995).

Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.1 and about 50 mg/kg body weight per day of the protease inhibitor compound described herein are useful in a monotherapy for the prevention and treatment of HCV mediated disease. Typically, the pharmaceutical composition of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Preferably, such preparations contain from about 20% to about 80% active compound.

- As the skilled artisan will appreciate, lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound
5 employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the infection, the patient's disposition to the infection and the judgment of the treating physician. Generally, treatment is initiated with small dosages substantially less than the optimum dose of the peptide. Thereafter, the dosage is increased by small
10 increments until the optimum effect under the circumstances is reached. In general, the compound is most desirably administered at a concentration level that will generally afford antivirally effective results without causing any harmful or deleterious side effects.
- 15 When the composition of this invention comprises a combination of a compound of formula I, including a pharmaceutically acceptable salt or ester thereof, and one or more additional therapeutic or prophylactic agent, both the compound and the additional agent should be present at dosage levels of between about 10 to 100%, and more preferably between about 10 and 80% of the dosage normally
20 administered in a monotherapy regimen.


When these compounds or their pharmaceutically acceptable salts and esters are formulated together with a pharmaceutically acceptable carrier, the resulting composition may be administered *in vivo* to mammals, such as man, to inhibit HCV
25 NS3 protease or to treat or prevent HCV virus infection. Such treatment may also be achieved using a compound of this invention in combination with another antiviral agent. Preferred other antiviral agents are described within the Definitions section and the section of preferred pharmaceutical compositions according to this invention and include, but are not limited to: α -, β -, δ -, ω -, γ -and τ -interferon, ribavirin,
30 amantadine; other inhibitors of HCV NS3 protease; inhibitors of HCV polymerase; inhibitors of other targets in the HCV life cycle, which include but not limited to, helicase, NS2/3 protease, or internal ribosome entry site (IRES); or combinations thereof. The additional agents may be combined with compounds of this invention to create a single dosage form. Alternatively these additional agents may be

- separately administered to a mammal as part of a multiple dosage form.
- Accordingly, another embodiment of this invention provides a method of inhibiting HCV NS3 protease activity in a mammal by administering a compound of the formula I, including a pharmaceutically acceptable salt or ester thereof.
- In a preferred embodiment, this method is useful in decreasing the NS3 protease activity of the hepatitis C virus infecting a mammal.
- As discussed above, combination therapy is contemplated wherein a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, is co-administered with at least one additional antiviral agent. Preferred antiviral agents are described hereinbefore and examples of such agents are provided in the Definitions section. These additional agents may be combined with the compounds of this invention to create a single pharmaceutical dosage form. Alternatively these additional agents may be separately administered to the patient as part of a multiple dosage form, for example, using a kit. Such additional agents may be administered to the patient prior to, concurrently with, or following the administration of a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof.
- A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, set forth herein may also be used as a laboratory reagent. Furthermore a compound of this invention, including a pharmaceutically acceptable salt or ester thereof, may also be used to treat or prevent viral contamination of materials and therefore reduce the risk of viral infection of laboratory or medical personnel or patients who come in contact with such materials (e.g. blood, tissue, surgical instruments and garments, laboratory instruments and garments, and blood collection apparatuses and materials).
- A compound of formula (I), including a pharmaceutically acceptable salt or ester thereof, set forth herein may also be used as a research reagent. A compound of formula (I), including a pharmaceutically acceptable salt or ester thereof, may also be used as positive control to validate surrogate cell-based assays or *in vitro* or *in vivo* viral replication assays.

Methodology

The compounds of the present invention are synthesized according to a general process as illustrated in Scheme I (wherein **CPG** is a carboxyl protecting group and 5 **APG** is an amino protecting group):

Scheme I



Briefly, the P1, P2, and P3 groups can be linked by well known peptide coupling 10 techniques. The P1, P2, and P3 groups may be linked together in any order as long as the final compound corresponds to peptides of Formula (I). For example, P3 can be linked to P2-P1 ; or P1 linked to P3-P2.

Generally, peptides are elongated by deprotecting the α -amino group of the N-terminal residue and coupling the unprotected carboxyl group of the next suitably N-protected amino acid through a peptide linkage using the methods described. This 15 deprotection and coupling procedure is repeated until the desired sequence is obtained. This coupling can be performed with the constituent amino acids in stepwise fashion, as depicted in Scheme I, or by solid phase peptide synthesis according to the method originally described in Merrifield, J. Am. Chem. Soc., 20 (1963), 85, 2149-2154, the disclosure of which is hereby incorporated by reference.

Coupling between two amino acids, an amino acid and a peptide, or two peptide fragments can be carried out using standard coupling procedures such as the azide method, mixed carbonic-carboxylic acid anhydride (isobutyl chloroformate) method, carbodiimide (dicyclohexylcarbodiimide, diisopropylcarbodiimide, or water-soluble 25 carbodiimide) method, active ester (p-nitrophenyl ester, N-hydroxysuccinic imido ester) method, Woodward reagent K-method, carbonyldiimidazole method, phosphorus reagents or oxidation-reduction methods. Some of these methods

(especially the carbodiimide method) can be enhanced by adding 1-hydroxybenzotriazole. These coupling reactions can be performed in either solution (liquid phase) or solid phase.

More explicitly, the coupling step involves the dehydrative coupling of a free carboxyl of one reactant with the free amino group of the other reactant in the presence of a coupling agent to form a linking amide bond. Descriptions of such coupling agents are found in general textbooks on peptide chemistry, for example, M. Bodanszky, "Peptide Chemistry", 2nd rev ed., Springer-Verlag, Berlin, Germany, (1993). Examples of suitable coupling agents are *N,N'*-dicyclohexylcarbodiimide, 1-hydroxybenzotriazole in the presence of *N,N'*-dicyclohexylcarbodiimide or *N*-ethyl-*N'*-(3-dimethylamino)propyl]carbodiimide. A practical and useful coupling agent is the commercially available (benzotriazol-1-yloxy)tris-(dimethylamino)phosphonium hexafluorophosphate, either by itself or in the presence of 1-hydroxybenzotriazole. Another practical and useful coupling agent is commercially available 2-(1H-benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate. Still another practical and useful coupling agent is commercially available O-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate.

The coupling reaction is conducted in an inert solvent, e.g. dichloromethane, acetonitrile or dimethylformamide. An excess of a tertiary amine, e.g. diisopropylethylamine, *N*-methylmorpholine or *N*-methylpyrrolidine, is added to maintain the reaction mixture at a pH of about 8. The reaction temperature usually ranges between 0°C and 50°C and the reaction time usually ranges between 15 min and 24 h.

When a solid phase synthetic approach is employed, the C-terminal carboxylic acid is attached to an insoluble carrier (usually polystyrene). These insoluble carriers contain a group that will react with the carboxylic group to form a bond that is stable to the elongation conditions but readily cleaved later. Examples of which are: chloro- or bromomethyl resin, hydroxymethyl resin, trityl resin and 2-methoxy-4-alkoxy-benzylalcohol resin.

Many of these resins are commercially available with the desired C-terminal amino acid already incorporated. Alternatively, the amino acid can be incorporated on the solid support by known methods (Wang, S.-S., *J. Am. Chem. Soc.*, (1973), 95, 1328; Atherton, E.; Shepard, R.C. "Solid-phase peptide synthesis; a practical approach"

IRL Press: Oxford, (1989); 131-148). In addition to the foregoing, other methods of peptide synthesis are described in Stewart and Young, "Solid Phase Peptide Synthesis", 2nd ed., Pierce Chemical Co., Rockford, IL (1984); Gross, Meienhofer, Udenfriend, Eds., "The Peptides: Analysis, Synthesis, Biology", Vol. 1, 2, 3, 5, and 9, 5 Academic Press, New-York, (1980-1987); Bodansky et al., "The Practice of Peptide Synthesis" Springer-Verlag, New-York (1984), the disclosures of which are hereby incorporated by reference.

The functional groups of the constituent amino acids generally must be protected during the coupling reactions to avoid formation of undesired bonds. The protecting groups that can be used are listed in Greene et al., "Protective Groups in Organic Synthesis", John Wiley & Sons, New York (1991) and "The Peptides: Analysis, Synthesis, Biology", Vol. 3, Academic Press, New York (1981), the disclosures of which are hereby incorporated by reference.

10 The α -carboxyl group of the C-terminal residue is usually protected as an ester (CPG) that can be cleaved to give the carboxylic acid. Protecting groups that can be used include: 1) alkyl esters such as methyl, trimethylsilylethyl and *tert*-butyl, 2) aralkyl esters such as benzyl and substituted benzyl, or 3) esters that can be cleaved by mild base treatment or mild reductive means such as trichloroethyl and phenacyl esters.

15 20 The α -amino group of each amino acid to be coupled to the growing peptide chain must be protected (APG). Any protecting group known in the art can be used. Examples of such groups include: 1) acyl groups such as formyl, trifluoroacetyl, phthalyl, and *p*-toluenesulfonyl; 2) aromatic carbamate groups such as benzylloxycarbonyl (Cbz or Z) and substituted benzylloxycarbonyls, and 9-fluorenylmethyloxycarbonyl (Fmoc); 3) aliphatic carbamate groups such as *tert*-butyloxycarbonyl (Boc), ethoxycarbonyl, diisopropylmethoxycarbonyl, and allyloxycarbonyl; 4) cyclic alkyl carbamate groups such as cyclopentyloxycarbonyl and adamantlyloxycarbonyl; 5) alkyl groups such as triphenylmethyl and benzyl; 6) trialkylsilyl such as trimethylsilyl; and 7) thiol containing groups such as 25 phenylthiocarbonyl and dithiasuccinoyl. The preferred α -amino protecting group is either Boc or Fmoc. Many amino acid derivatives suitably protected for peptide synthesis are commercially available.

30 The α -amino protecting group of the newly added amino acid residue is cleaved

- prior to the coupling of the next amino acid. When the Boc group is used, the methods of choice are trifluoroacetic acid, neat or in dichloromethane, or HCl in dioxane or in ethyl acetate. The resulting ammonium salt is then neutralized either prior to the coupling or *in situ* with basic solutions such as aqueous buffers, or
- 5 tertiary amines in dichloromethane or acetonitrile or dimethylformamide. When the Fmoc group is used, the reagents of choice are piperidine or substituted piperidine in dimethylformamide, but any secondary amine can be used. The deprotection is carried out at a temperature between 0°C and room temperature (RT) usually 20 - 22°C.
- 10 Any of the amino acids having side chain functionalities must be protected during the preparation of the peptide using any of the above-described groups. Those skilled in the art will appreciate that the selection and use of appropriate protecting groups for these side chain functionalities depend upon the amino acid and presence of other protecting groups in the peptide. The selection of such protecting
- 15 groups is important in that the group must not be removed during the deprotection and coupling of the α -amino group.


For example, when Boc is used as the α -amino protecting group, the following side chain protecting group are suitable: *p*-toluenesulfonyl (tosyl) moieties can be used to protect the amino side chain of amino acids such as Lys and Arg; acetamidomethyl, 20 benzyl (Bn), or *tert*-butylsulfonyl moieties can be used to protect the sulfide-containing side chain of cysteine; benzyl (Bn) ethers can be used to protect the hydroxy-containing side chains of serine, threonine or hydroxyproline; and benzyl esters can be used to protect the carboxy-containing side chains of aspartic acid and glutamic acid.

- 25 When Fmoc is chosen for the α -amine protection, usually *tert*-butyl based protecting groups are acceptable. For instance, Boc can be used for lysine and arginine, *tert*-butyl ether for serine, threonine and hydroxyproline, and *tert*-butyl ester for aspartic acid and glutamic acid. The triphenylmethyl (trityl) moiety can be used to protect the sulfide-containing side chain of cysteine.
- 30 Once the elongation of the peptide is completed, all of the protecting groups are removed. When a liquid phase synthesis is used, the protecting groups are removed in whatever manner is dictated by the choice of protecting groups. These procedures are well known to those skilled in the art.

When a solid phase synthesis is used, the peptide is cleaved from the resin simultaneously with the removal of the protecting groups. When the Boc protection method is used in the synthesis, treatment with anhydrous HF containing additives such as dimethyl sulfide, anisole, thioanisole, or *p*-cresol at 0°C is the preferred 5 method for cleaving the peptide from the resin. The cleavage of the peptide can also be accomplished by other acid reagents such as trifluoromethanesulfonic acid/trifluoroacetic acid mixtures. If the Fmoc protection method is used, the N-terminal Fmoc group is cleaved with reagents described earlier. The other 10 protecting groups and the peptide are cleaved from the resin using solution of trifluoroacetic acid and various additives such as anisole, etc.

In general, the compounds of formula I, and intermediates therefore, are prepared by known methods using reaction conditions which are known to be suitable for the reactants. Several such methods are disclosed in WO 00/09543, WO 00/09558 and US Pat. No. 6,323,180.

15 The following schemes illustrate convenient processes using known methods for preparing the compounds of formula 1 when R^c is OH and R¹ is vinyl.

Scheme II:

Briefly, dipeptide **1** can be prepared by coupling of P1 (vinyl-ACCA) with *trans*-hydroxyproline and the stereochemistry at the 4-hydroxy proline can be inverted via a Mitsunobu reaction. These procedures as well as the synthesis of P1 have been described in WO 00/09543 and WO 00/09558 and US Pat. No. 6,323,180.


Synthesis of capping group B

The synthesis of the P3 moieties and their capping groups B used for the synthesis of compounds of formula (I) are described, in part, in WO 00/59929, which in turn incorporates the teachings of WO 00/09558 and WO 00/09543, all of which are herein incorporated by reference.

Different capping groups B are introduced in the following manner:

- In the case where X is O, protected P3 or the whole peptide or a peptide segment is coupled to an appropriate chloroformate that is either commercially available or for which the synthesis is well known in the art. For Boc- derivatives (Boc)₂O is used.

For example:



- a) Cyclobutanol is treated with phosgene to furnish the corresponding
 5 chloroformate.
 b) The chloroformate is treated with the desired NH₂-tripeptide in the presence of a base such as triethylamine to afford the cyclobutylcarbamate.


When X is -NH-, protected P3 or the whole peptide or a peptide segment is treated
 10 with phosgene followed by amine as described in SynLett. Feb 1995; (2); 142-144. Alternatively the whole peptide or a peptide segment is treated with an alkyl isocyanate.

Synthesis of P2 substituents:


- 15 The synthesis of 2-carbomethoxy-4-hydroxy-7-methoxyquinoline **6a** and 2-carbomethoxy-7-dimethylamino-4-hydroxyquinoline **6b** are described in WO 00/59929, which in turn incorporates the teachings of WO 00/09558 and WO 00/09543, all of which are herein incorporated by reference.
- 20 4-hydroxy-2-carbomethoxyquinoline derivatives are introduced in the tripeptide *via* a Mitsunobu reaction (Mitsunobu (1981), *Synthesis*, January, 1-28; Rano *et al.*, (1995), *Tet. Lett.* 36(22), 3779-3792; Krchnak *et al.*, (1995), *Tet. Lett.* 36(5), 62193-6196; Richter *et al.*, (1994), *Tet. Lett.* 35(27), 4705-4706). Tripeptides **7** can be converted to the desired compounds by first converting the 2-carbomethoxy group into a bromoketone *via* the diazoketone intermediate as shown in the examples and the final conversion into the aminothiazole is done by condensing bromo ketones **8** with the required thioureas **9**. Final hydrolysis of the methyl ester is achieved by treatment with LiOH in methanol.
- 25 Alternatively, instead of substituted thioureas **9**, the reaction can be performed with
- 30

commercially available thiourea giving the corresponding unsubstituted aminothiazole which can be reacted with any chloroformate to give the corresponding thiazolyl carbamate derivative or with any alkylisocyanate to give the corresponding thiazolyl urea derivative as shown in scheme III.

5

Scheme III:

Alternatively the compounds can be synthesized starting with a preformed dipeptide bromoketone such as 12 in scheme IV. This bromoketone can be converted to the required aminothiazole derivatives by reaction with thioureas 9 followed by incorporation of the carbamate or urea P3 group using standard coupling conditions as described above.

Scheme IV:

The method described in Scheme IV can also be used for the synthesis of the
 5 claimed compounds by making a permutation library.

Compounds of formula I wherein R^c is $NHSO_2R^s$ as defined herein are prepared by coupling the corresponding acid of formula I (i.e. R^c is hydroxy) with an appropriate sulfonamide of formula $R^s SO_2NH_2$ in the presence of a coupling agent under
 10 standard conditions. Although several commonly used coupling agents can be employed, TBTU and HATU have been found to be practical. The sulfonamides are available commercially or can be prepared by known methods.

EXAMPLES

15 The present invention is illustrated in further detail by the following non-limiting examples. Other specific ways of synthesis or resolution can be found in WO 00/59929, WO 00/09558 and WO 00/09543.

20 Temperatures are given in degrees Celsius. Solution percentages express a weight to volume relationship, and solution ratios express a volume to volume relationship, unless stated otherwise. Nuclear magnetic resonance (NMR) spectra were

recorded on a Bruker 400 MHz spectrometer; the chemical shifts (δ) are reported in parts per million. Flash chromatography was carried out on silica gel (SiO_2) according to Still's flash chromatography technique (W.C. Still et al., J. Org. Chem., (1978), 43, 2923).

5


Abbreviations used in the examples include:
DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene; DCM: dichloromethane; DIAD: diisopropylazodicarboxylate; DIEA: diisopropylethylamine; DIPEA: diisopropylethyl amine; DMF: N, N-dimethylformamide; DMAP: 4-(dimethylamino) pyridine; EtOAc: ethyl acetate; HATU: [O-7-azabenzotriazol-1-yl]-1,1,3,3-tetramethyluronium hexafluorophosphate]; HPLC: high performance liquid chromatography; MS: mass spectrometry (MALDI-TOF: Matrix Assisted Laser Desorption Ionization-Time of Flight, FAB: Fast Atom Bombardment); Me: methyl; MeOH: methanol; Ph: phenyl; R.T.: room temperature (18 to 22°); *tert*-butyl or t-butyl: 1,1-dimethylethyl; Tbg: *tert*-butyl glycine; *tert*-leucine; TBTU: 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyl uronium tetrafluoroborate; TFA: trifluoroacetic acid; and THF: tetrahydrofuran.

P1 BUILDING BLOCKS


20 P1 moieties of compounds of Formula (I) were prepared using the protocols outlined in WO 00/59929, published October 12, 2000, and WO 00/09543, published on February 24, 2000, the contents of both of which are herein incorporated by reference. In particular, reference is made to pages 33-35, Example 1 of WO00/59929 and Pages 56-69 , Example 9 – 20 of WO00/09543 for the preparation of 1-aminocyclopropanecarboxylic acid P1 moieties.

P2 BUILDING BLOCKS

30 P2 moieties of compounds of Formula (I) were prepared using the protocols outlined in WO00/59929, published October 12, 2000, and WO00/09543, published on February 24, 2000, the contents of both of which are herein incorporated by reference.

EXAMPLE 1**Synthesis of 2-carbomethoxy-7-dimethylamino-4-hydroxyquinoline (6b):****Step 1:**

Commercially available N,N-dimethyl-1,3-phenylene diamine dihydrochloride salt (12 g) was neutralized with solid NaHCO₃ (partitioned between H₂O and EtOAc). After neutralization, the phases were separated and the organic phase dried and concentrated to give a brownish oil (7.8 g, 57.3 mmol) which was used as is in the next step. Dimethyl acetylene dicarboxylate 15 (7.044 mL, 57.3 mmol) was dissolved in MeOH and treated with the neutralized aniline 16 (portionwise) in MeOH at 0°C. Considerable heat was generated (exothermic reaction). The mixture (brown) was heated at 65°C for 2 hours. The brown solution was concentrated to dryness, extracted into EtOAc and washed with sat. NaHCO₃ (aq), followed by brine, dried (MgSO₄), filtered, and concentrated. The crude mixture was purified by flash chromatography using a 10% EtOAc/hexane solvent to afford 12 g of compound 17. MS: electrospray: (M + H)⁺; 279 and (M - H)⁻; 277.


20 Step 2:

The diester precursor 17 (6 gm, 21.56 mmol) was dissolved in diphenyl ether (10 mL) which was preheated to 245°C in a sand bath. The mixture was heated a further 7 minutes (addition lowers the temperature to about 230°C). The final internal temperature was 245°C. The darkened solution was removed from the sand bath and air cooled for a few minutes and then further cooled by an ice bath. The product precipitated out after a few minutes. The solution was left a few hours to allow the

product to completely precipitate and then was filtered to give a yellow solid. The same protocol was duplicated with the remaining half of the diester precursor (6 g) to give a yellow solid. The solids (identical) were combined and suspended in Et₂O before being filtered. The yellow solid was washed several times with diethyl ether and then with hexane to give 6.25 g of the title compound **6b** (59%).
 5 Reverse Phase HPLC: (homogeneity = 96%).
 Mass Spectrum: electrospray, (M + Na)⁺; 269, (M - H)⁻; 244.9.


EXAMPLE 2

10 Preparation of 3-thioallophanic acid isopropyl ester (**9a**)



Potassium thiocyanate (4.8 g, 0.049 mol) was dissolved in water (10 mL) and acetonitrile (30 mL) before being treated with pyridine (0.25 mL, 3.09 mmol, 6.3 mol%). The solution was cooled to 0°C (ice bath) and then treated dropwise with isopropylchloroformate in toluene (51 mL, 0.051 mol, 1.05 eq.) over 2 hours. The mixture was stirred rapidly to ensure mixing of the layers to give an orange solution.
 15 The mixture was allowed to stir overnight and then cooled to 0°C before being treated with 10% HCl (aq) (2 mL) to dissolve the salts. This mixture was then treated with ammonia in dioxane (0.5M solution, 110 mL, 1.12 eq.) from a dropping funnel over 2 h. The mixture was allowed to warm to RT and stirred overnight. The mixture was quenched with water (100 mL) and the phases separated. The aqueous phase was re-extracted with EtOAc and the combined organic phase dried over MgSO₄,
 20 filtered and concentrated to give a yellow solid. This was dissolved in a minimum amount of EtOAc (ca. 15 mL) and then precipitated with hexane (ca. 100 mL) to give a yellow precipitate. This material was filtered and then washed with hexane to give the desired urea as a yellow solid (3.7 g, 47%).
 25


¹H NMR (400MHz, DMSO-d₆) δ 10.76 (s, 1H), 9.22 (s, 1H), 9.00 (s, 1H), 4.91-4.82 (m, 1H), 1.22 (d, J = 7.3 Hz, 6H).
 30

EXAMPLE 3**Preparation of 3-thioallophanic acid cyclopentyl ester (9b)**

5 Using the procedure described above but using cyclopentylchloroformate instead of isopropylchloroformate gave the desired compound (9b).

P3 BUILDING BLOCKS


P3 moieties of compounds of Formula (I) were generally prepared using the 10 protocols outlined in WO00/59929, published October 12, 2000, and WO00/09543, published on February 24, 2000, the contents of both of which are herein incorporated by reference.

EXAMPLE 4**Preparation of carbamate 2a**

20 THF (350 mL) was added to a flask containing carbonic acid cyclopentyl ester 2,5-dioxo-pyrrolidin-1-yl ester (9.00 g; 39.6 mmol) and *tert*-butyl glycine (6.24 g; 47.5 mmol) resulting in a suspension. Distilled water (100 mL) was added with vigorous stirring. A small amount of solid remained undissolved. Triethylamine (16.6 mL; 119 mmol) was then added resulting in a homogenous solution which was stirred at R.T. After 2.5 h, the THF was evaporated and the aqueous residue diluted with water (100 mL). The reaction was rendered basic by the addition of 1 N NaOH (25 mL - final pH >10). The solution was washed with EtOAc (2 x 200 mL) and the aqueous phase acidified with 1 N HCl (ca. 70 mL - final pH <2). The turbid solution was extracted with EtOAc (200 + 150 mL). The extract was dried ($MgSO_4$) and evaporated to give carbamate 2a as a white solid (8.68 g).


Preparation of other carbamates

- Using the procedure described above and using appropriate combinations of *tert*-butyl glycine, cyclopentyl glycine, or cyclohexyl glycine and carbonic acid cyclobutyl-, cyclopentyl-, or cyclohexyl ester 2,5-dioxo-pyrrolidin-1-yl ester, carbamates of the following formulas were prepared:



EXAMPLE 5

Preparation of Urea 3a



- A solution of *tert*-butyl glycine benzyl ester hydrochloride salt (2.55 g; 9.89 mmol) in THF (20 mL) and pyridine (2.0 mL; 24.73 mmol) was cooled to 0°C. Phenyl chloroformate (1.30 mL; 10.19 mmol) was added dropwise to the cooled solution.
- The resulting suspension was stirred for 5 min at 0°C, then at R.T. for 1.5 h. The reaction mixture was diluted with EtOAc, washed with 10% citric acid (2x) water (2x) saturated NaHCO₃ (2x), water (2x) and brine (1x), dried (MgSO₄), filtered and evaporated to obtain the crude compound as a nearly colorless oil (3.73 g; >100%; assume 9.89 mmol). The crude product (1.01 g; 2.97 mmol) was dissolved in DMSO (6.5 mL) and cyclopentylamine was added dropwise. The reaction mixture was stirred at R.T. for 45 min. The reaction mixture was diluted with EtOAc. The organic phase was washed with 10% citric acid (2x), water (2x), saturated NaHCO₃ (2x), water (2x) and brine (1x), dried (MgSO₄), filtered and evaporated to give the crude

cyclopentyl urea -Tbg-OBn product as a nearly colorless oil. The crude material was purified by flash column chromatography with silica using hexane:EtOAc 9:1 to remove the less polar impurities and 7:3 to elute the purified product as a thick colorless oil (936 mg; 95%). The benzyl ester product (936 mg; 2.82 mmol) was 5 deprotected under a hydrogen filled balloon at R.T. in absolute ethanol (15 mL) solution by stirring the solution with 10% Pd/C (93.6 mg) for 5.5h. The reaction mixture was filtered through a 0.45 micron filter and evaporated to dryness to provide urea **3a** as a white solid (668.8 mg ; 98%)

¹H NMR (400 MHz,DMSO-d₆): δ 12.39 (s, 1H), 6.09 (d, J = 7.4 Hz, 1H), 5.93 (d, J = 9.4 Hz, 1H), 3.90 (d, J = 9.4 Hz, 1H), 3.87-3.77 (m, 1H), 1.84-1.72 (m, 2H), 10 1.63-1.42 (m, 4H), 1.30-1.19 (m, 2H), 0.89 (s, 9H).
M.S.(electrospray) : 241.0 (M-H)⁻ 243.0 (M+H)⁺. Reverse Phase HPLC Homogeneity (0.06% TFA; CH₃CN : H₂O) : 99%.


15

TRIPEPTIDE ANALOGS

EXAMPLE 6

Preparation of Compound 105

Step 1: Synthesis of tripeptide 7a:




20 To tripeptide **5a** (1.0 g; 2.09 mmol) dissolved in THF (35 mL), hydroxyquinoline **6a** (729 mg; 3.13 mmol) and triphenylphosphine (1.1 g ; 4.2 mmol) were added. The yellow suspension was cooled in an ice bath and DIAD (821 μL , 4.2 mmol) was added dropwise. The solution was stirred at ice bath temperature for 30 min, and at R.T. for 16 h. The solution was evaporated to dryness and the residue was 25 dissolved in EtOAc, washed with a saturated sodium bicarbonate solution (2x), water (2x) and brine (1x), dried (MgSO₄), filtered and evaporated to obtain a yellow oil which precipitated on standing. The crude solid was suspended in DCM and the insoluble material was filtered off. The solution was concentrated and the residue purified by flash chromatography in hexane : EtOAc; 5 : 5 to remove all less polar

impurities and in $\text{CHCl}_3\text{:EtOAc}$; 80:20 until all the $\text{Ph}_3\text{P=O}$ has eluted. The desired compound was eluted with $\text{CHCl}_3\text{:EtOAc}$; 65:35 as a white solid (1 g; 70% yield). M.S.(electrospray) : 693.3 ($\text{M}-\text{H}$)⁻ 695.4 ($\text{M}+\text{H}$)⁺ 717.4 ($\text{M}+\text{Na}$)⁺. Reverse Phase HPLC Homogeneity (0.06% TFA ; $\text{CH}_3\text{CN} : \text{H}_2\text{O}$) : 99%.

5


Step 2 : Selective monohydrolysis of ester 7a:



Tripeptide **7a** (1 g; 1.44 mmol) was dissolved in THF (10 mL), MeOH (5 mL), water (5 mL) and a 1N aqueous solution of NaOH (1.5 mL) were added and the solution was stirred at R.T. for 2h. The mixture was evaporated to dryness and then co-evaporated with MeOH:toluene (1:1; 4x), toluene (2x) and diethyl ether (2x) to obtain salt **18** (water-free) as a white flaky solid (1.04 g; 100% yield)
M.S.(electrospray) : 679.3 ($M-H^-$)⁻ 681.3 ($M+H^+$)⁺ 703.3 ($M+Na^+$)⁺.
Reverse Phase HPLC Homogeneity (0.06% TFA ; CH₃CN : H₂O) : 95%.

15

Step 3 : Synthesis of diazoketone 19:



Sodium salt 18 (assume 1.44 mmol) was dissolved in THF (16 mL), triethylamine (301 μ L; 2.16 mmol) was added and the solution cooled to 0°C .


20 Isobutylchloroformate (280 μ L; 2.16 mmol) was added dropwise and the white suspension was stirred at 0°C for 75 min, followed by the addition of a solution of diazomethane (0.67M in diethyl ether; 13 mL; 8.64 mmol). The reaction mixture is stirred 1h at 0°C, 45 min at R.T. and evaporated to provide a thick suspension. This suspension was dissolved in EtOAc and water. The organic solution was washed

with saturated NaHCO_3 (2x), water (2x) and brine (1x), dried (MgSO_4), filtered and evaporated to give the diazoketone **19** as an ivory solid (crude material used for next step; assume 1.44 mmol).

M.S.(electrospray) : 703.3 ($\text{M}-\text{H}$)⁻ 705.3 ($\text{M}+\text{H}$)⁺. Reverse Phase HPLC

- 5 Homogeneity (0.06% TFA ; $\text{CH}_3\text{CN} : \text{H}_2\text{O}$) : 91%.

Step 4 : Synthesis of bromoketone **8a**:




- At 0°C, to a solution of diazoketone **19** (1.44 mmol) in THF (24 mL) was added 10 dropwise an HBr solution (1.0 mL) and the mixture was stirred for 1h. The solution was diluted with EtOAc, washed with a saturated NaHCO_3 solution(2x), water (2x) and brine (1x), dry (MgSO_4), filtered and evaporated to give the desired bromoketone **8a** as an ivory-beige solid (1.1 g; assume 1.44 mmol).

M.S.(electrospray) : 757.3 (M) 759.3 (M+2)

15

Step 5: Preparation of aminothiazolyl derivative **10a**:




- 20 α -Bromoketone **8a** (0.82 g; 1.08 mmol) was combined with commercially available thiourea (167 mg ; 2.19 mmol) in isopropanol (20 mL) and the yellow solution was heated at 75°C for 1 hour. The solution was cooled to R.T. and evaporated to dryness. The residue was dissolved in EtOAc. The EtOAc solution was washed with saturated NaHCO_3 (2x), water (1x) and brine (1x), dried (MgSO_4), and evaporated to give the crude product **10a** as a yellow solid (0.78 g, 1.06 mmol,

98%),


M.S.(electrospray) : 733.2 (M-H)⁻ 735.2 (M+H)⁺. Reverse Phase HPLC Homogeneity (0.06 % TFA; CH₃CN : H₂O) : 93 %.

5 Step 6: Preparation of intermediate 20



To a solution of the thiazolyl amine **10a** (55 mg ; 0.075 mmol) in dichloromethane (3.0 mL) was added DIEA (70 μ L ; 0.402 mmol) followed by 1M isopropyl chloroformate / toluene (950 μ L ; 0.947 mmol). The mixture was placed in a preheated oil bath (40° C) and stirred overnight. The reaction was found to be incomplete by analytical HPLC and additional reagent was added (DIEA: 35 μ L; 0.201 mmol and 380 μ L ; 0.379 mmol), stirred at an oil bath temperature of 40° C for 7 hours and overnight at room temperature. The reaction was concentrated, diluted with EtOAc, washed with water, saturated sodium bicarbonate and brine, dried ($MgSO_4$), filtered and evaporated to dryness to obtain the crude product **20** (60 mg; 0.073 mmol ; 98 % yield).

Step 7: Final hydrolysis to compound 105



A solution of methyl ester **20** (60 mg; 0.073 mmol) in THF (2.5 mL), MeOH (0.5 mL) and an aqueous solution of LiOH (37 mg ; 0.881 mmol) in water (1 mL) was stirred overnight . The organic solution is concentrated to provide an off white suspension. The crude material was purified by preparatory HPLC (YMC CombiScreen ODS-AQ,


50 x20 mm ID S-5 micron, 120 Å ; $\lambda=220\text{nm}$) using a linear gradient and 0.06% TFA CH₃CN / H₂O . The pure fractions were combined , concentrated and lyophilized to provide compound 105 (from Table 1) as the TF salt (27 mg ; 46 % yield).

5 ¹H NMR (400 MHz,DMSO-d₆): ca, 9:1 mixture of rotamers, major isomer
 10 description; δ 12.02 (br s, 1H), 8.59 (s, 1H), 8.49-8.26 (m, 1H), 8.18 (d, J = 9.0 Hz, 1H), 7.70-7.48 (m, 2H), 7.25-7.15 (m, 1H), 7.07 (d, J = 8.2 Hz, 1H), 5.77-5.65 (m, 1H), 5.63-5.53 (m, 1H), 5.23-5.15 (m, 1H), 5.10-4.95 (m, 2H), 4.60-4.50 (m, 1H), 4.49-4.38 (m, 2H), 4.09-4.02 (m, 1H), 3.98-3.88 (m, 1H), 3.95 (s, 3H), 2.62-2.52 (m, 1H), 2.34-2.23 (m, 1H), 2.05-1.96 (m, 1H), 1.70-1.38 (m, 7H), 1.31 (d, J = 6.3 Hz, 6H), 1.31-1.01 (m, 3H), 0.96 (s, 9H).

M.S.(electrospray) : 805.3 (M-H)⁻ 807.3 (M+H)⁺ . Reverse Phase HPLC Homogeneity (0.06 % TFA; CH₃CN : H₂O) : 99 %

EXAMPLE 7


15 Synthesis of compound 102



Compound 102

Compound 102 is prepared using the same procedure as the one described in example 6 but using methyl chloroformate instead of isopropyl chloroformate in step 6.

20 ¹H NMR (400 MHz,DMSO-d₆): ca, 9:1 mixture of rotamers, major isomer
 25 description; δ 8.56 (s, 1H), 8.47-8.20 (m, 1H), 8.20-8.12 (m, 1H), 7.67-7.45 (m, 2H), 7.24-7.14 (m, 1H), 7.01 (d, J = 8.3 Hz, 1H), 5.78-5.66 (m, 1H), 5.62-5.51 (m, 1H), 5.23-5.16 (m, 1H), 5.09-5.03 (m, 1H), 4.64-4.54 (m, 1H), 4.50-4.39 (m, 2H), 4.07 (d, J = 8.6 Hz, 1H), 3.99-3.92 (m, 1H), 3.95 (s, 3H), 3.80 (s, 3H), 2.63-2.53 (m, 1H), 2.34-2.24 (m, 1H), 2.06-1.97 (m, 1H), 1.77-1.22 (m, 10H), 0.97 (s, 9H).
 M.S.(electrospray) : 777.2 (M-H)⁻ 779.2 (M+H)⁺ . Reverse Phase HPLC Homogeneity (0.06 % TFA; CH₃CN : H₂O) : 99 %


EXAMPLE 8**Synthesis of Compound 101**

Compound 101

Compound 101 is prepared using the same procedure as the one described in example 6 but using isobutyl chloroformate instead of isopropyl chloroformate in step 6.


¹H NMR (400 MHz, DMSO-d₆): ca, 9:1 mixture of rotamers, major isomer description; δ 8.57 (s, 1H), 8.42-8.31 (m, 1H), 8.17 (d, J = 9.2 Hz, 1H), 7.66-7.52 (m, 2H), 7.25-7.16 (m, 1H), 7.01 (d, J = 8.3 Hz, 1H), 5.78-5.66 (m, 1H), 5.62-5.55 (m, 1H), 5.23-5.16 (m, 1H), 5.09-5.03 (m, 1H), 4.61-4.53 (m, 1H), 4.50-4.40 (m, 2H), 4.06 (d, J = 8.6, 1H), 4.03 (d, J = 5.4 Hz, 2H), 3.99-3.92 (m, 1H), 3.95 (s, 3H), 2.62-2.53 (m, 1H), 2.34-2.25 (m, 1H), 2.05-1.93 (m, 2H), 1.69-1.22 (m, 10H), 0.97 (s, 9H), 0.95 (d, J = 6.7 Hz, 6H).

M.S.(electrospray) : 819.5 (M-H)⁻ 821.4 (M+H)⁺. Reverse Phase HPLC
Homogeneity (0.06 % TFA; CH₃CN : H₂O) : 98 %


EXAMPLE 9**Synthesis of Compound 103**

Compound 103

The synthesis starts with aminothiazole derivative 10a described in step 6 of example 6.

Step 1:

To a solution of the thiazolylamine derivative **10a** (50 mg ; 0.068 mmol) in dichloromethane (2.0 mL) was added commercially available ethylisocyanate (17 μL ; 0.215 mmol) followed by DIEA (36 μL ; 0.207 mmol). The reaction was stirred overnight and found to be incomplete by analytical HPLC. Additional reagent was added (ethylisocyanate: 2X 17 μL ; 0.430 mmol) but the reaction went to completion only after being placed in a preheated oil bath (40°C) for 3 hours. The reaction was concentrated, diluted with EtOAc, washed with saturated sodium bicarbonate and brine, dried (MgSO_4), filtered and evaporated to dryness to obtain the methyl ester **21** (59 mg; >0.068 mmol ; >100 % yield).

Step 2: Hydrolysis of methyl ester **21**

To a solution of methyl ester **21** (0.068 mmol) in a 3 mL mixture of $\text{THF:H}_2\text{O}$ (2.5:1), was added a 1N solution of NaOH (0.55 mL, 0.55 mmol). 0.5 mL of MeOH was required to obtain an homogeneous solution. The resulting reaction was stirred at room temperature for 4 hours. The organic solution was concentrated to provide an off white suspension. The crude material was purified by preparatory HPLC (YMC Combscreen ODS-AQ, 50 x20 mm ID S-5 micron, 120 A ; $\lambda=220\text{nm}$) using a linear gradient and 0.06% TFA $\text{CH}_3\text{CN} / \text{H}_2\text{O}$. The pure fractions were combined, concentrated and lyophilized to provide the product **103** as the TF salt (34 mg; 55% yield).

¹H NMR (400 MHz, DMSO-d₆): ca, 9:1 mixture of rotamers, major isomer
description: δ 10.65 (s, 1H), 8.57 (s, 1H), 8.40-8.20 (m, 1H), 8.18 (d, J = 9.2 Hz, 1H),
 7.72-7.54 (m, 2H), 7.27-7.18 (m, 1H), 7.01 (d, J = 8.0 Hz, 1H), 6.82-6.68 (m, 1H),
 5.78-5.66 (m, 1H), 5.66-5.59 (m, 1H), 5.23-5.16 (m, 1H), 5.09-5.03 (m, 1H), 4.59-
 4.41 (m, 3H), 4.06 (d, J = 8.2, 1H); 3.99-3.91 (m, 1H), 3.95 (s, 3H), 3.25-3.15 (m,
 2H), 2.63-2.54 (m, 1H), 2.36-2.26 (m, 1H), 2.07-1.98 (m, 1H), 1.70-1.23 (m, 10H),
 1.10 (t, J = 7.0 Hz, 3H), 0.97 (s, 9H).

M.S.(electrospray) : 790.2 (M-H)⁻ 792.3 (M+H)⁺. Reverse Phase HPLC
 Homogeneity (0.06 % TFA; CH₃CN : H₂O) : 99 %


10

DIPEPTIDE ANALOGS

EXAMPLE 10

Synthesis of bromoketone 12a:

Step 1: Monohydrolysis of diester 11a:




15

Dipeptide **11a** (4.0 g ; 7.02 mmol) was dissolved in THF (20 mL) and MeOH (10 mL), water (10 mL) and a 1N NaOH aqueous solution (1.05 equivalents; 7.4 mL) was added. The solution stirred at R.T. for 2 h 45 min. The mixture was evaporated to dryness. The residue was diluted with water, frozen and lyophilized to provide sodium salt **22a** as a white amorphous solid (4.28 g).

M.S. (electrospray) : 554.2 ($M-H^-$)⁻ 556.3 ($M+H^+$)⁺ 578.2 ($M+Na^+$)⁺

Reverse Phase HPLC Homogeneity (0.06% TFA : CH₃CN : H₂O) : 96%.

Step 2: synthesis of dipeptide diazoketone **23a**:




Sodium salt **22a** (assume 7.02 mmol) was dissolved in THF (78 mL); triethylamine (1.37 mL; 9.83 mmol) was added and the solution cooled to 0°C .

Isobutylchloroformate (1.28 mL; 9.83 mmol) was added dropwise and the white suspension was stirred at 0°C for 2h, , followed by the addition of a solution of diazomethane (0.67M in diethyl ether; 63 mL; 42.13 mmol). The reaction mixture was stirred 1 h at 0°C, 1.25 h at R.T. and evaporated to provide a thick suspension. This suspension was dissolved in EtOAc and water. The organic solution was washed with saturated NaHCO₃ (2x), water (2x) and brine (1x), dried (MgSO₄), filtered and evaporated to give the diazoketone **23a** as an beige solid (crude material used for next step; assume 7.02 mmol).


M.S.(electrospray) : 578.2 ($M-H^-$)⁻ 580.3 ($M+H^+$)⁺. Reverse Phase HPLC Homogeneity (0.06% TFA ; CH₃CN : H₂O) : 90%.

Step 3: synthesis of dipeptide bromoketone 12a



At 0°C, to a solution of diazoketone **23a** (assume 1.44 mmol) in THF (116 mL) was added dropwise a 48% aqueous HBr solution (5.1 mL) and the mixture was stirred for 2h. The solution was diluted with EtOAc, washed with a saturated NaHCO₃ solution(2x), water (2x) and brine (1x), dry (MgSO₄), filtered and evaporated to give the desired bromoketone **12a** as a beige solid (4.25 g; 6.72 mmol).

M.S.(electrospray) : 632 (M) 634.2 (M+2)


EXAMPLE 11**Synthesis of bromo ketone 12b:**

12b

Using the same procedure as described in Example 10 but using 2-carbomethoxy-7-dimethylamino-4-hydroxyquinoline (**6b**) for the synthesis of diester **11b**, the title bromoketone **12b** was obtained

EXAMPLE 12**Permutation library:**

Both bromo ketones **12a** and **12b** were used in a permutation library for the parallel synthesis of compounds as shown in the following scheme V:


Scheme V

15

Step 1: Formation of the aminothiazole ring

A series of 8-mL vials were disposed in a reaction block from an ACT496 synthesizer (from Advanced Chemtech). In each vial was added the thiourea-R²² of interest (0.055 mmol), the bromoketone (0.05 mmol, 31.63 mg OMe or 32.28 mg


NMe₂) and isopropanol (500 µL) (see the diagram at the end for the position of each reactant in the block). The closed vials were heated at 70°C for 1 h. The solvent was then evaporated using a vacuum centrifuge and was co-evaporated with 1,2-dichloroethane. The crude products were dried under high vacuum overnight.



Step 2: Removal of the Boc protecting group

All the vials were treated with 30% TFA in DCM (500 µL) for 1h. All vials were transferred on a vacuum centrifuge to remove the volatile material.

Step 3: Coupling
In each vial was added the corresponding carbamate and urea acid (0.07 mmol), HATU (0.07 mmol, 26.6 mg) and DIPEA (0.3 mmol, 50 µL) in 500 µL of DMSO and the reaction mixture was allowed to proceed overnight.



Step 4: Saponification and Purification


All reactions were diluted with 400 µL of DMSO and 200 µL THF. A solution of 400

μL of aqueous 2N LiOH (0.8 mmol) was added to each vial and allowed to proceed overnight after which time, the mixture was neutralized by the addition of 400 μL of AcOH. All compounds were purified by semi-prep reversed-phase HPLC (Symmetry column 5 cm x 19 cm, $\text{CH}_3\text{CN} / \text{H}_2\text{O}$ 0.06% TFA gradient).

5

Compound 108

Compound arising from combination of bromo ketone 12a, P3 fragment carbamate 2a-c and thiourea 9a:



Compound 108


10

^1H NMR (400 MHz, DMSO-d_6): ca, 9:1 mixture of rotamers, major isomer description; δ 12.46 (br s, 1H), 12.00 (br s, 1H), 8.58 (s, 1H), 8.45-8.07 (m, 2H), 7.70-7.38 (m, 2H), 7.25-7.09 (m, 1H), 7.08 (d, $J = 8.0$ Hz, 1H), 5.78-5.65 (m, 1H), 5.60-5.47 (m, 1H), 5.23-5.15 (m, 1H), 5.09-4.95 (m, 2H), 4.50-4.39 (m, 2H), 4.21-4.03 (m, 2H), 3.99-3.92 (m, 1H), 3.95 (s, 3H), 2.33-2.23 (m, 1H), 2.06-1.96 (m, 1H), 1.83-1.44 (m, 6H), 1.31 (d, $J = 6.0$ Hz, 6H), 1.32-1.08 (m, 7H), 0.97 (s, 9H).
M.S.(electrospray) : 819.4 ($M-\text{H}$)⁻ 821.3 ($M+\text{H}$)⁺. Reverse Phase HPLC Homogeneity (0.06 % TFA; $\text{CH}_3\text{CN} : \text{H}_2\text{O}$) : 100 %

20

Compound 109

Compound arising from combination of bromo ketone 12a, P3 fragment carbamate 2b-a and thiourea 9a:




Compound 109

¹H NMR (400 MHz,DMSO-d₆): ca, 85:15 mixture of rotamers, major isomer description; δ 12.52 (br s, 1H), 11.99 (br s, 1H), 8.54 (s, 1H), 8.40-8.05 (m, 2H), 7.73-7.40 (m, 2H), 7.32-7.13 (m, 1H), 7.25 (d, J = 7.9 Hz, 1H), 5.77-5.65 (m, 1H), 5.63-5.48 (m, 1H), 5.24-5.15 (m, 1H), 5.10-4.95 (m, 2H), 4.59-4.36 (m, 3H), 4.04-5. 3.88 (m, 2H), 3.94 (s, 3H), 2.34-2.21 (m, 1H), 2.04-1.94 (m, 1H), 1.77-1.36 (m, 14H), 1.31 (d, J = 6.0 Hz, 6H), 1.28-1.21 (m, 2H), 1.18-0.83 (m, 6H).
M.S.(electrospray) : 831.4 (M-H)⁻ 833.4 (M+H)⁺. Reverse Phase HPLC Homogeneity (0.06 % TFA; CH₃CN : H₂O) : 99 %

10 **Compound 115**

Compound arising from combination of bromo ketone 12b, P3 fragment carbamate 2a-b and thiourea 9a:




Compound 115

¹H NMR (400 MHz,DMSO-d₆): ca, 9:1 mixture of rotamers, major isomer description; δ 12.48 (br s, 1H), 12.08 (br s, 1H), 8.59 (s, 1H), 8.65-8.47 (m, 1H), 8.08 (d, J = 9.1 Hz, 1H), 7.58-7.46 (m, 1H), 7.37-7.14 (m, 3H), 5.79-5.10 (m, 2H), 5.26-5.16 (m, 1H), 5.11-4.98 (m, 2H), 4.55-4.39 (m, 2H), 4.38-4.25 (m, 1H), 4.03-3.88 (m, 2H), 3.16 (s, 6H), 2.63-2.54 (m, 1H), 2.35-2.26 (m, 1H), 2.06-1.92 (m, 3H), 1.88-1.75 (m, 2H), 1.66-1.53 (m, 2H), 1.44-1.34 (m, 1H), 1.31 (d, J = 6.3 Hz, 6H), 1.30-1.22 (m, 1H), 0.95 (s, 9H).
M.S.(electrospray) : 804.4 (M-H)⁻ 806.4 (M+H)⁺. Reverse Phase HPLC Homogeneity (0.06 % TFA; CH₃CN : H₂O) : 96 %

25 **Compound 202**

Compound arising from combination of bromo ketone 12a, P3 fragment urea 3a and thiourea 9b:




Compound 202

¹H NMR (400 MHz, DMSO-d₆): ca, 85:15 mixture of rotamers, major isomer description; δ 12.48 (br s, 1H), 12.00 (br s, 1H), 8.58 (s, 1H), 8.45-8.13 (m, 2H), 7.75-7.41 (m, 2H), 7.26-7.07 (m, 1H), 6.03 (d, J = 6.6 Hz, 1H), 5.92 (d, J = 9.6 Hz, 1H), 5.79-5.66 (m, 1H); 5.63-5.49 (m, 1H), 5.25-5.16 (m, 2H), 5.10-5.04 (m, 1H), 4.57-4.38 (m, 2H), 4.21-4.12 (m, 1H), 4.02-3.94 (m, 1H), 3.95 (s, 3H), 3.60-3.30 (m, under H₂O, 1H), 2.35-2.23 (m, 1H), 2.07-1.98 (m, 1H), 1.97-1.85 (m, 2H), 1.80-1.36 (m, 14H), 1.30-1.02 (m, 3H), 0.95 (s, 9H).

M.S.(electrospray) : 830.4 (M-H)⁻ 832.4 (M+H)⁺. Reverse Phase HPLC.
10 Homogeneity (0.06 % TFA; CH₃CN : H₂O) : 100 %

Compound 203

Compound arising from combination of bromo ketone 12b, P3 fragment urea 3a and thiourea 9a:



Compound 203

¹H NMR (400 MHz, DMSO-d₆): ca, 85:15 mixture of rotamers, major isomer description; δ 12.48 (br s, 1H), 12.08 (br s, 1H), 8.59 (s, 1H), 8.62-8.48 (m, 1H), 8.10 (d, J = 9.2 Hz, 1H), 7.50 (br s, 1H), 7.27-7.12 (m, 2H), 6.01 (d, J = 6.9 Hz, 1H), 5.89 (d, J = 9.4 Hz, 1H), 5.78-5.57 (m, 2H), 5.26-5.16 (m, 1H), 5.11-4.97 (m, 2H), 4.61-4.51 (m, 1H), 4.48-4.39 (m, 1H), 4.17-4.08 (m, 1H), 4.02-3.94 (m, 1H), 3.55-3.25 (m, under H₂O, 1H), 3.14 (s, 6H), 2.37-2.26 (m, 1H), 2.16-1.98 (m, 1H), 1.81-1.21 (m, 9H), 1.31 (d, J = 6.3 Hz, 6H), 1.19-1.00 (m, 2H); 0.94 (s, 9H).

M.S.(electrospray) : 817.4 (M-H)⁻ 819.4 (M+H)⁺. Reverse Phase HPLC

Homogeneity (0.06 % TFA; CH₃CN : H₂O) : 98 %

EXAMPLE 13

NS3-NS4A protease assay

- 5 The enzymatic assay used to evaluate the present compound is described in WO 00/09543 and WO 00/59929.

EXAMPLE 14

Cell Based HCV RNA Replication Assay

10 Cell Culture

Huh7 cells that stably maintain a subgenomic HCV replicon were established as previously described (Lohman et al., 1999. Science 285: 110-113) and designated as the S22.3 cell-line. S22.3 cells are maintained in Dulbecco's Modified Earle Medium (DMEM) supplemented with 10% FBS and 1 mg/mL neomycin (Standard Medium). During the assay, DMEM medium supplemented with 10% FBS, containing 0.5% DMSO and lacking neomycin was used (Assay Medium). 16 hours prior to compound addition, S22.3 cells are trypsinized and diluted to 50 000 cells/mL in Standard Medium. 200 µL (10 000 cells) are distributed into each well of a 96-well plate. The plate was then incubated at 37° with 5% CO₂ until the next day.

20

Reagents and Materials:

Product	Company	Catalog #	Storage
DMEM	Wisent Inc.	10013CV	4°C
DMSO	Sigma	D-2650	RT
Dulbecco's PBS	Gibco-BRL	14190-136	RT
Fetal Bovine Serum	Bio-Whittaker	14-901F	-20°C/4°C
Neomycin (G418)	Gibco-BRL	10131-027	-20°C/4°C
Trypsin-EDTA	Gibco-BRL	25300-054	-20°C/4°C
96-well plates	Costar	3997	RT
PVDF 0.22µm Filter Unit	Millipore	SLGV025LS	RT
Deep-Well Titer Plate Polypropylene	Beckman	267007	RT

Preparation of Test Compound

10 μ L of test compound (in 100% DMSO) was added to 2 mL of Assay Medium for a final DMSO concentration of 0.5% and the solution was sonicated for 15 min and filtered through a 0.22 μ M Millipore Filter Unit. 900 μ L was transferred into row A of a
5 Polypropylene Deep-Well Titer Plate. Rows B to H, contain 400 μ L aliquots of Assay Medium (containing 0.5% DMSO), and are used to prepare serial dilutions (1/2) by transferring 400 μ L from row to row (no compound was included in row H).

Application of test compound to cells

10 Cell culture medium was aspirated from the 96-well plate containing the S22.3 cells. 175 μ L of assay medium with the appropriate dilution of test compound was transferred from each well of the compound plate to the corresponding well of the cell culture plate (row H was used as the "No inhibition control"). The cell culture plate was incubated at 37°C with 5% CO₂ for 72h.

15

Extraction of Total Cellular RNA

Following the 72h incubation period, the total cellular RNA was extracted from the S22.3 cells of the 96-well plate using the RNeasy 96 kit (Qiagen®, RNeasy Handbook. 1999.). Briefly, assay medium was completely removed from cells and 20 100 μ L of RLT buffer (Qiagen®) containing 143 mM β -mercaptoethanol was added to each well of the 96-well cell-culture plate. The microplate was gently shaken for 20 sec. 100 μ L of 70% ethanol was then added to each microplate well, and mixed by pipetting. The lysate was removed and applied to the wells of a RNeasy 96 (Qiagen®) plate that was placed on top of a Qiagen® Square-Well Block. The 25 RNeasy 96 plate was sealed with tape and the Square-Well Block with the RNeasy 96 plate was loaded into the holder and placed in a rotor bucket of a 4K15C centrifuge. The sample was centrifuged at 6000 rpm (~5600 x g) for 4 min at room temperature. The tape was removed from the plate and 0.8 mL of Buffer RW1 (Qiagen® RNeasy 96 kit) was added to each well of the RNeasy 96 plate. The RNeasy 96 plate was sealed with a new piece of tape and centrifuged at 6000 rpm for 4 min at 30 room temperature. The RNeasy 96 plate was placed on top of another clean Square-Well Block, the tape removed and 0.8 mL of Buffer RPE (Qiagen® RNeasy 96 kit) was added to each well of the RNeasy 96 plate. The RNeasy 96 plate was sealed with a new piece of tape and centrifuged at 6000 rpm for 4 min at

room temperature. The tape was removed and another 0.8 mL of Buffer RPE (Qiagen® RNeasy 96 kit) was added to each well of the RNeasy 96 plate. The RNeasy 96 plate was sealed with a new piece of tape and centrifuged at 6000 rpm for 10 min at room temperature. Tape was removed, the RNeasy 96 plate was 5 placed on top of a rack containing 1.2-mL collection microtubes. The RNA was eluted by adding 50 µL of RNase-free water to each well, sealing plate with a new piece of tape and incubated for 1 min at room temperature. The plate was then centrifuged at 6000 rpm for 4 min at room temperature. The elution step was repeated with a second volume of 50 µL RNase-free water. The microtubes with 10 total cellular RNA are stored at -70°.

Quantification of Total Cellular RNA

RNA was quantified on the STORM® system (Molecular Dynamics®) using the RiboGreen® RNA Quantification Kit (Molecular Probes®). Briefly, the RiboGreen 15 reagent was diluted 200-fold in TE (10 mM Tris-HCl pH = 7.5, 1 mM EDTA). Generally, 50 µL of reagent was diluted in 10 mL TE. A Standard Curve of ribosomal RNA was diluted in TE to 2 µg/mL and pre-determined amounts (100, 50, 40, 20, 20, 10, 5, 2 and 0 µL) of the ribosomal RNA solution are then transferred in a new 96-well plate (COSTAR # 3997) and the volume was completed to 100 µL with TE. 25 Generally, column 1 of the 96-well plate was used for the standard curve and the other wells are used for the RNA samples to be quantified. 10 µL of each RNA sample that was to be quantified, was transferred to the corresponding well of the 96-well plate and 90 µL of TE was added. One volume (100 µL) of diluted RiboGreen reagent was added to each well of the 96-well plate and incubated for 2 to 5 minutes at room temperature, protected from light (a 10 µL RNA sample in a 200 µL final volume generates a 20X dilution). The fluorescence intensity of each well was measured on the STORM® system (Molecular Dynamics®). A standard curve was created on the basis of the known quantities of the ribosomal RNA and the resulting fluorescent intensities. The RNA concentration in the experimental 30 samples was determined from the standard curve and corrected for the 20X dilution.

Reagents and Materials:

Product	Company	Catalog #	Storage
DEPC	Sigma	D5758	4°C
EDTA	Sigma	E5134	RT
Trizma-Base	Sigma	T8524	RT
Trizma-HCl	Sigma	T7149	RT
Collection Tube Strips	Qiagen	19562	RT
Ribogreen RNA Quantitation Kit	Molecular Probe	R11490	-20°C
Rneasy 96 Kit	Qiagen	74183	RT
Square-Well Blocks	Qiagen	19573	RT

Real-Time RT-PCR

The Real-Time RT-PCR was performed on the ABI Prism 7700 Sequence Detection System using the TaqMan EZ RT-PCR Kit from (Perkin-Elmer Applied Biosystems®). RT-PCR was optimized for the quantification of the 5' IRES of HCV RNA by using the Taqman technology (Roche Molecular Diagnostics Systems) similar to the technique previously described (Martell et al., 1999. J. Clin. Microbiol. 37: 327-332). The system exploits the 5'-3' nucleolytic activity of AmpliTaq DNA polymerase. Briefly, the method utilizes a dual-labeled fluorogenic hybridization probe (PUTR Probe) that specifically anneals to the template between the PCR primers (primers 8125 and 7028). The 5' end of the probe contains a fluorescent reporter (6-carboxyfluorescein [FAM]) and the 3' end contains a fluorescent quencher (6-carboxytetramethylrhodamine [TAMRA]). The FAM reporter's emission spectrum was suppressed by the quencher on the intact hybridization probe. Nuclease degradation of the hybridization probe releases the reporter, resulting in an increase in fluorescence emission. The ABI Prism 7700 sequence detector measures the increase in fluorescence emission continuously during the PCR amplification such that the amplified product was directly proportion to the signal.

The amplification plot was analysed early in the reaction at a point that represents the logarithmic phase of product accumulation. A point representing a defined detection threshold of the increase in the fluorescent signal associated with the exponential growth of the PCR product for the sequence detector was defined as the cycle threshold (C_T). C_T values are inversely proportional to the quantity of input HCV RNA; such that under identical PCR conditions, the larger the starting

concentration of HCV RNA, the lower the C_T . A standard curve was created automatically by the ABI Prism 7700 detection system by plotting the C_T against each standard dilution of known HCV RNA concentration.

- 5 Reference samples for the standard curve are included on each RT-PCR plate. HCV Replicon RNA was synthesized (by T7 transcription) *in vitro*, purified and quantified by OD₂₆₀. Considering that 1 µg of this RNA = 2.15 X 10¹¹ RNA copies, dilutions are made in order to have 10⁸, 10⁷, 10⁶, 10⁵, 10⁴, 10³ or 10² genomic RNA copies / 5 µL. Total cellular Huh-7 RNA was also incorporated with each dilution (50ng / 5 µL). 10 5 µL of each reference standard (HCV Replicon + Huh-7 RNA) was combined with 45 µL of Reagent Mix, and used in the Real-Time RT-PCR reaction.

- 15 The Real-Time RT-PCR reaction was set-up for the experimental samples that were purified on RNeasy 96 –well plates by combining 5 µL of each total cellular RNA sample with 45 µL of Reagent Mix.

Reagents and Materials:

Product	COMPANY	Catalog #	Storage
TaqMan EZ RT-PCR Kit	PE Applied Biosystems	N808-0236	-20°C
MicroAmp Optical Caps	PE Applied Biosystems	N801-0935	RT
MicroAmp Optical 96-Well Reaction Plate	PE Applied Biosystems	N801-0560	RT

Reagent Mix preparation:

Component	Volume for one sample (µL)	Volume for One Plate (µL) (91 samples + Dead Volume)	Final conc.
Rnase-free water	16.5	1617	
5X TaqMan EZ buffer	10	980	1X
Mn(OAc) ₂ (25 mM)	6	588	3 mM
dATP (10 mM)	1.5	147	300 µM
dCTP (10 mM)	1.5	147	300 µM
dGTP (10 mM)	1.5	147	300 µM
dUTP (20 mM)	1.5	147	600 µM
Forward Primer (10 µM)	1	98	200 nM

Reverse Primer (10 µM)	1	98	200 nM
PUTR probe (5 µM)	2	196	200 nM
rTth DNA polymerase (2.5 U/µL)	2	196	0.1 U/µL
AmpErase UNG (1 U/µL)	0.5	49	0.01 U/µL
Total Volume	45	4410	

Forward Primer Sequence (SEQ ID. 1): 5' - ACG CAG AAA GCG TCT AGC CAT GGC GTT AGT - 3'

- 5 **Reverse Primer Sequence (SEQ ID NO. 2):** 5' - TCC CGG GGC ACT CGC AAG CAC CCT ATC AGG - 3'

Note: Those primers amplify a region of 256-nt present within the 5' untranslated region of HCV.

10

PUTR Probe Sequence (SEQ ID NO. 3): [6FAM] - TGG TCT GCG GAA CCG GTG AGT ACA CC - [TAMRA]

- 15 **No Template Controls (NTC):** On each plate, 4 wells are used as "NTC". For these controls, 5 µL of water are added to the well in place of RNA.

Thermal Cycling Conditions:

50°C 2 min
60°C 30 min
20 95°C 5 min

95°C 15 sec }
60°C 1 min } for 2 cycles

25 90°C 15 sec }
60°C 1 min } for 40 cycles

Following the termination of the RT-PCR reaction the data analysis requires setting of threshold fluorescence signal for the PCR plate and a standard curve was constructed by plotting the C_T value versus RNA copy number used in each reference reaction. The C_T values obtained for the assay samples are used to
5 interpolate an RNA copy number based on the standard curve.

Finally, the RNA copy number was normalized (based on the RiboGreen RNA quantification of the total RNA extracted from the cell culture well) and expressed as genome equivalents / μg of total RNA [g.e./ μg].

10 The RNA copy number [g.e./ μg] from each well of the cell culture plate was a measure of the amount of replicating HCV RNA in the presence of various concentrations of inhibitor. The % inhibition was calculated with the following equation:

$$100 - [(g.e./\mu\text{g} \text{ inh})/(g.e./\mu\text{g} \text{ ctl}) \times 100].$$

15 A non-linear curve fit with the Hill model was applied to the inhibition-concentration data, and the 50% effective concentration (EC_{50}) was calculated by the use of SAS software (Statistical Software System; SAS Institute, Inc. Cary, N.C.).

20 When the compounds of this invention were evaluated in the preceding enzymatic and cell based assays, the compounds were found to be highly active. More specifically, the compounds had IC_{50} values below 0.1 μM in the NS3-NS4A protease assay, and EC_{50} values below 0.5 μM in the cell based HCV RNA replication assay.

25

EXAMPLE 15

Specificity assays

The specificity assays used to evaluate the selectivity of this compound are described in WO 00/09543.

30

When the compounds were evaluated in the specificity assays, the compounds of formula I were found to be selective in that they do not show significant inhibition in the Human Leukocyte Elastase and Cathepsin B assays.

EXAMPLE 16**Pharmacokinetic properties**

The present compounds also show good pharmacokinetic properties such as detectable plasma levels in the rat at 1 hour and 2h after an oral dose of 4 or 5 mg/kg.

More explicitly, the following assay, an *in vivo* oral absorption screen, was used to determine plasma levels of test compounds in a rat after oral administration:

10 **Materials and Methods:**

1. **Method used to pool compounds ("cassette selection"):**

The selection of compounds to be pooled into a "cassette" was based on their structural similarity and physicochemical properties. A solid phase extraction method applicable to all the selected compounds was established. Based on the initial testing where each compound was spiked into rat plasma and run through HPLC or HPLC/MS at a concentration of 0.5 μ M, the retention time, ionic mass, and the possible separation among compounds by HPLC and/or HPLC/MS were used as basis for pooling 3-4 compounds into one "cassette".

20 **2. Oral vehicle and compound preparation:**

Each "cassette" contains 3-4 compounds at 5 or 4 mg/kg for each compound. The cassettes were prepared as an oral suspension in 0.5% aqueous methylcellulose and 0.3% of polyoxyethylene (20) sorbitan monooleate (Tween-80). The dosing volume was 10 mL/kg via oral gavage.

25

3. **Dosing and plasma sampling:**

Male Sprague Dawley rats were fasted overnight in individual cages, with access to aqueous 10% dextrose. Two rats were dosed with each "cassette". Plasma samples (~1 mL) were collected at 1 and 2 h post-dosing from the 2 rats and pooled for extraction and analysis.

30

4. **Compound extraction and analysis:**

From each cassette, plasma samples at 1 and 2h, blank plasma, blank plasma spiked with all the compounds at 0.5 μ M of each, are extracted by the solid phase


extraction method. Samples were analyzed by HPLC and HPLC/MS for comparison purpose. Plasma concentrations are estimated based on the single concentration of 0.5 μM standard.

5 Results

When assayed in the preceding screen, compounds of this invention were found to present levels in the plasma at the 1 hour and 2 hour intervals following oral administration, achieving blood plasma levels up to 0.5 μM and 0.6 μM respectively.

10

TABLE 1




Cpd	B	R ³	R ²¹	R ²²	R ^c	m/z (M+H) ⁺
101			-OCH ₃		-OH	821.4
102			-OCH ₃		-OH	779.2
103			-OCH ₃		-OH	672.2
104			-OCH ₃		-OH	833.4

Cpd	B	R ³	R ²¹	R ²²	R ^C	m/z (M+H) ⁺
105			-OCH ₃		-OH	807.3
106			-OCH ₃		-OH	819.4
107			-OCH ₃		-OH	793.4
108			-OCH ₃		-OH	821.3
109			-OCH ₃		-OH	833.4
110			-OCH ₃		-OH	847.4
111			-OCH ₃		-OH	847.4
112			-OCH ₃		-OH	845.4
113			-OCH ₃		-OH	859.4
114			-OCH ₃		-OH	873.4

Cpd	B	R ³	R ²¹	R ²²	R ^c	m/z (M+H) ⁺
115			N(CH ₃) ₂		-OH	806.4
116			N(CH ₃) ₂		-OH	820.4
117			N(CH ₃) ₂		-OH	834.4
118			N(CH ₃) ₂		-OH	832.4
119			N(CH ₃) ₂		-OH	846.4
120			N(CH ₃) ₂		-OH	860.4
121			N(CH ₃) ₂		-OH	832.4
122			N(CH ₃) ₂		-OH	846.4
123			N(CH ₃) ₂		-OH	860.4
124			N(CH ₃) ₂		-OH	858.4

Cpd	B	R ³	R ²¹	R ²²	R ^c	m/z (M+H) ⁺
125			N(CH ₃) ₂		-OH	872.4
126			N(CH ₃) ₂		-OH	886.5
127			N(CH ₃) ₂		-OH	845.4


TABLE 2



Cpd	B	R ³	R ²¹	R ²²	R ^c	m/z (M+H) ⁺
201			-OCH ₃		-OH	806.3
202			-OCH ₃		-OH	832.4
203			-N(CH ₃) ₂		-OH	819.4

WHAT IS CLAIMED IS:

1. A racemate, diastereoisomer, or optical isomer of a compound of formula (I):



wherein **B** is (C_{1-10}) alkyl, (C_{3-7}) cycloalkyl, or (C_{1-4}) alkyl- (C_{3-7}) cycloalkyl,

- a) wherein said cycloalkyl and alkyl-cycloalkyl may be mono-, di- or tri-substituted with (C_{1-3}) alkyl; and
- b) wherein said alkyl, cycloalkyl, and alkyl-cycloalkyl may be mono- or di-substituted with substituents selected from hydroxy and $O-(C_{1-4})$ alkyl; and
- c) wherein all said alkyl-groups may be mono-, di- or tri-substituted by halogen; and
- d) wherein in all said cycloalkyl-groups being 5-, 6- or 7-membered, one or two $-CH_2-$ groups not being directly linked to each other may be replaced by $-O-$ such that the O-atom is linked to the group **X** via at least two C-atoms;

X is O or NH;

R³ is (C_{2-8}) alkyl, (C_{3-7}) cycloalkyl, or (C_{1-3}) alkyl- (C_{3-7}) cycloalkyl, wherein all of said alkyl and cycloalkyl groups may be mono-, di- or tri-substituted with (C_{1-4}) alkyl;

R²¹ is H, halogen, -OH, (C_{1-6}) alkyl, (C_{3-6}) cycloalkyl, $-(C_{1-4})$ alkyl- (C_{3-6}) cycloalkyl, (C_{1-6}) alkoxy, $-O-(C_{3-6})$ cycloalkyl, $-O-(C_{1-4})$ alkyl- (C_{3-6}) cycloalkyl or $-N(R^{24})_2$, wherein each **R**²⁴ is independently: H, (C_{1-6}) alkyl, $-(C_{3-6})$ cycloalkyl, or $-(C_{1-4})$ alkyl- (C_{3-6}) cycloalkyl;

R²² is $-NR^{N2}COOR^0$ or $-NR^{N2}CONR^{N3}R^{N1}$, wherein
R⁰ is selected from (C₁₋₈)alkyl, (C₃₋₇)cycloalkyl, and (C₁₋₄)alkyl-(C₃₋₇)cycloalkyl, wherein said cycloalkyl and alkyl-cycloalkyl may be mono-, di- or tri-substituted with (C₁₋₃)alkyl;
R^{N1} is H or **R⁰** as defined above; and
R^{N2} and **R^{N3}** are independently selected from H and methyl;

R¹ is ethyl or vinyl;

R^C is hydroxy or $NHSO_2R^S$ wherein **R^S** is (C₁₋₆)alkyl, (C₃₋₇)cycloalkyl or (C₁₋₆)alkyl-(C₃₋₇)cycloalkyl, phenyl, naphthyl, pyridinyl, (C₁₋₄)alkyl-phenyl, (C₁₋₄)alkyl-naphthyl or (C₁₋₄)alkyl-pyridinyl; all of which optionally being mono-, di- or tri-substituted with substituents selected from halogen, hydroxy, cyano, (C₁₋₄)alkyl, O-(C₁₋₆)alkyl, -CO-NH₂, -CO-NH((C₁₋₄)alkyl), -CO-N((C₁₋₄)alkyl)₂, -NH₂, -NH((C₁₋₄)alkyl), -N((C₁₋₄)alkyl)₂, wherein (C₁₋₄)alkyl and O-(C₁₋₆)alkyl are optionally mono-, di- or trisubstituted with halogen; and all of which optionally being monosubstituted with nitro;
or a pharmaceutically acceptable salt or ester thereof.

2. The compound according to claim 1, wherein

- B** is (C₁₋₁₀)alkyl, (C₃₋₇)cycloalkyl or (C₁₋₄)alkyl-(C₃₋₇)cycloalkyl,
 - a) wherein said cycloalkyl and alkyl-cycloalkyl may be mono-, di- or tri-substituted with (C₁₋₃)alkyl; and
 - b) wherein said alkyl, cycloalkyl and alkyl-cycloalkyl may be mono- or di-substituted with substituents selected from hydroxy and O-(C₁₋₄)alkyl; and
 - c) wherein all said alkyl-groups may be mono-, di- or tri-substituted by halogen; and
 - d) wherein in all said cycloalkyl-groups being 5-, 6- or 7-membered, one or two -CH₂-groups not being directly linked to each other may be replaced by -O- such that the O-atom is linked to the group X via at least two C-atoms;

X is O or NH;

R³ is (C₂₋₈)alkyl, (C₃₋₇)cycloalkyl or (C₁₋₃)alkyl-(C₃₋₇)cycloalkyl, wherein said cycloalkyl groups may be mono-, di- or tri-substituted with (C₁₋₄)alkyl;

R²¹ H, halogen, -OH, (C₁₋₆)alkyl, (C₃₋₆)cycloalkyl, -(C₁₋₄)alkyl-(C₃₋₆)cycloalkyl, (C₁₋₆)alkoxy, -O-(C₃₋₆)cycloalkyl, -O-(C₁₋₄)alkyl-(C₃₋₆)cycloalkyl or -N(R²⁴)₂, wherein each R²⁴ is independently: H, (C₁₋₆)alkyl, -(C₃₋₆)cycloalkyl, or -(C₁₋₄)alkyl-(C₃₋₆)cycloalkyl;

R²² is -NR^{N2}COOR⁰ or -NR^{N2}CONR^{N3}R^{N1}, wherein R⁰ is selected from (C₁₋₈)alkyl, (C₃₋₇)cycloalkyl and (C₁₋₄)alkyl-(C₃₋₇)cycloalkyl, wherein said cycloalkyl, alkyl-cycloalkyl may be mono-, di- or tri-substituted with (C₁₋₃)alkyl; R^{N1} is H or R⁰ as defined above; and R^{N2} and R^{N3} are independently selected from H and methyl;

R¹ is ethyl or vinyl;

R^c is hydroxy or NHSO₂R^s wherein R^s is (C₁₋₆)alkyl, (C₃₋₇)cycloalkyl or (C₁₋₆)alkyl-(C₃₋₇)cycloalkyl, phenyl, naphthyl, pyridinyl, (C₁₋₄)alkyl-phenyl, (C₁₋₄)alkyl-naphthyl or (C₁₋₄)alkyl-pyridinyl; all of which optionally being mono-, di- or tri-substituted with substituents selected from halogen, hydroxy, cyano, (C₁₋₄)alkyl, O-(C₁₋₆)alkyl, -CO-NH₂, -CO-NH((C₁₋₄)alkyl), -CO-N((C₁₋₄)alkyl)₂, -NH₂, -NH((C₁₋₄)alkyl), -N((C₁₋₄)alkyl)₂; and all of which optionally being monosubstituted with nitro;

or a pharmaceutically acceptable salt or ester thereof.


3. The compound according to claim 1, wherein R²¹ is selected from halogen, -OH, (C₁₋₃)alkoxy or N(R²⁴)₂, wherein each R²⁴ is independently: H or (C₁₋₆)alkyl.

4. The compound according to claim 3, wherein R^{21} is selected from -OH, -OCH₃ and -N(CH₃)₂.
5. The compound according to one or more of the preceding claims, wherein R^{22} is -NHCOOR⁰ or -NHCONHR^{N1}, wherein R^{N1} and R⁰ are defined as in claim 1.
6. The compound according to one or more of the preceding claims, wherein R⁰ and R^{N1}, are selected from the group consisting of methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl; wherein said cycloalkyl and alkyl-cycloalkyl groups optionally being substituted by 1 to 3 substituents selected from methyl and ethyl.
7. The compound according to one or more of the preceding claims, wherein B is selected from (C₁₋₄)alkyl, (C₃₋₇)cycloalkyl and (C₁₋₃)alkyl-(C₃₋₇)cycloalkyl,
 - a) wherein said cycloalkyl and alkyl-cycloalkyl may be mono-, di- or tri-substituted with (C₁₋₃)alkyl; and
 - b) wherein all of which may be mono- or di-substituted with substituents selected from hydroxy and O-(C₁₋₄)alkyl; and
 - c) wherein all said alkyl-groups may be mono-, di- or tri-substituted with fluorine or mono-substituted by chlorine or bromine; and
 - d) wherein in all said cycloalkyl-groups being 5-, 6- or 7-membered, one or two -CH₂-groups not being directly linked to each other may be replaced by -O- such that the O-atom is linked to the group X via at least two C-atoms.
8. The compound according to claim 7, wherein B is selected from ethyl, n-propyl, i-propyl, n-butyl, 1-methylpropyl, 2-methylpropyl, *tert*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl,
 - a) wherein each of said cycloalkyl and alkyl-cycloalkyl groups optionally being substituted by 1 to 3 substituents selected from methyl and ethyl;

- b) wherein each of said groups optionally being mono- or di-substituted with substituents selected from hydroxy, methoxy and ethoxy; and
 - c) wherein each of said alkyl groups may be mono-, di- or tri-substituted with fluorine or mono-substituted by chlorine or bromine and
 - d) wherein in all said cycloalkyl-groups being 5-, 6- or 7-membered, one or two -CH₂-groups not being directly linked to each other may be replaced by -O- such that the O-atom is linked to the group X via at least two C-atoms.
9. The compound according to claim 8, wherein **B** is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-methylcyclopentyl and 1-methylicyclohexyl.
10. The compound according to one or more of the preceding claims, wherein **R**³ is selected from ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, all of which optionally being substituted by 1 to 3 substituents selected from methyl, ethyl and propyl.
11. The compound according to claim 10, wherein **R**³ is selected from 1-methylethyl, 1,1-dimethylethyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, cyclopentyl, cyclohexyl, 1-methylcyclopentyl, 1-methylcyclohexyl, cyclopentylmethyl, cyclohexylmethyl, (1-methylcyclopentyl)methyl and (1-methylcyclohexyl)methyl.
12. The compound according to one or more of the preceding claims, wherein **R**¹ is vinyl.

13. The compound according to one or more of the preceding claims, wherein R^c is selected from hydroxy or $NHSO_2R^s$ wherein R^s is methyl, ethyl, n-propyl, i-propyl, n-butyl, 1-methylpropyl, 2-methylpropyl, *tert*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, phenyl, naphthyl, pyridinyl, phenylmethyl, naphthylmethyl or pyridinylmethyl,
 - a) all of which optionally being mono-, di- or tri-substituted with substituents selected from fluorine and methyl; and
 - b) all of which optionally being mono- or disubstituted with substituents selected from hydroxy, trifluoromethyl, methoxy and trifluoromethoxy; and
 - c) all of which optionally being monosubstituted with substituents selected from chlorine, bromine, cyano, nitro, -CO-NH₂, -CO-NHCH₃, -CO-N(CH₃)₂, -NH₂, -NH(CH₃) and -N(CH₃)₂.
14. The compound according to claim 13 wherein R^c is hydroxy, $NHSO_2$ -methyl, $NHSO_2$ -ethyl, $NHSO_2$ -(1-methyl)ethyl, $NHSO_2$ -propyl, $NHSO_2$ -cyclopropyl, $NHSO_2$ -cyclopropylmethyl, $NHSO_2$ -cyclobutyl, $NHSO_2$ -cyclopentyl or $NHSO_2$ -phenyl.
15. The compound according to claim 14 wherein the group R^c is hydroxy.
16. The compound according to claim 14 wherein the group R^c is $NHSO_2$ -cyclopropyl.
17. The compound according to one or more of the preceding claims, wherein X is O.
18. The compound according to one or more of the preceding claims, wherein X is NH.

19. The compound according to claim 1, represented by formula:



wherein R²¹ is -OCH₃ or N(CH₃)₂;

R²² is -NHCOOR⁰ or -NHCONHR^{N1}, wherein

R⁰ and R^{N1} is each independently selected from (C₁₋₄)alkyl or (C₃₋₆)cycloalkyl;

B is (C₄₋₆)cycloalkyl;

X is O or NH;

R³ is *tert*-butyl or cyclohexyl;

R^c is hydroxy or NHSO₂R^s wherein R^s is (C₁₋₄)alkyl, (C₃₋₆)cycloalkyl or phenyl;


or a pharmaceutically acceptable salt or ester thereof.

20. The compound according to claim 19, wherein R²¹ is -OCH₃; R²² is -NHCOOR⁰ wherein R⁰ is isopropyl or cyclopentyl; and R^s is cyclopropyl.

21. The compound according to claim 19 wherein R^c is hydroxy.

22. The compound according to claim 21 wherein R²¹ is -OCH₃ and R²² is -NHCOOR⁰ wherein R⁰ is isopropyl or cyclopentyl.

23. The compound according to claim 1 of the formula




wherein the substituents **B**, R^3 , R^{21} , R^{22} and R^c are defined according to the following table

Cpd	B	R^3	R^{21}	R^{22}	R^c
101			-OCH ₃		-OH
102			-OCH ₃		-OH
103			-OCH ₃		-OH
104			-OCH ₃		-OH
105			-OCH ₃		-OH
106			-OCH ₃		-OH
107			-OCH ₃		-OH
108			-OCH ₃		-OH
109			-OCH ₃		-OH
110			-OCH ₃		-OH

Cpd	B	R ³	R ²¹	R ²²	R ^c
111			-OCH ₃		-OH
112			-OCH ₃		-OH
113			-OCH ₃		-OH
114			-OCH ₃		-OH
115			N(CH ₃) ₂		-OH
116			N(CH ₃) ₂		-OH
117			N(CH ₃) ₂		-OH
118			N(CH ₃) ₂		-OH
119			N(CH ₃) ₂		-OH
120			N(CH ₃) ₂		-OH

Cpd	B	R ³	R ²¹	R ²²	R ^c
121			N(CH ₃) ₂		-OH
122			N(CH ₃) ₂		-OH
123			N(CH ₃) ₂		-OH
124			N(CH ₃) ₂		-OH
125			N(CH ₃) ₂		-OH
126			N(CH ₃) ₂		-OH
127			N(CH ₃) ₂		-OH

24. The compound according to claim 1 of the formula



wherein the substituents B, R³, R²¹, R²² and R^c are defined according to the following table

Cpd	B	R ³	R ²¹	R ²²	R ^c
201			-OCH ₃		-OH
202			-OCH ₃		-OH
203			-N(CH ₃) ₂		-OH

25. A pharmaceutical composition comprising an anti-hepatitis C virally effective amount of a compound of formula I according to one or more of the claims 1 to 24 or a pharmaceutically acceptable salt or ester thereof, in admixture with at least one pharmaceutically acceptable carrier medium or auxiliary agent.
26. The pharmaceutical composition according to claim 25 further comprising a therapeutically effective amount of at least one other antiviral agent.
27. The pharmaceutical composition according to claim 26, wherein said other antiviral agent is ribavirin.
28. The pharmaceutical composition according to claim 26, wherein said other antiviral agent is selected from another anti-HCV agent; HIV inhibitor, HAV inhibitor and HBV inhibitor.
29. The pharmaceutical composition according to claim 28 wherein said other anti-HCV agent is selected from immunomodulatory agents, other inhibitors of HCV NS3 protease, inhibitors of HCV polymerase and inhibitors of another target in the HCV life cycle.
30. The pharmaceutical composition according to claim 29 wherein said

immunomodulatory agent is selected from α -interferon and pegylated α -interferon.

31. The pharmaceutical composition according to claim 29, wherein said inhibitor of another target in the HCV life cycle is selected from inhibitors of: helicase, NS2/3 protease and internal ribosome entry site (IRES).
32. A method for the treatment or prevention of a hepatitis C viral infection in a mammal by administering to the mammal an anti-hepatitis C virally effective amount of a compound of formula I according to one or more of the claims 1 to 24, or a pharmaceutically acceptable salt or ester thereof.
33. A method for the treatment or prevention of a hepatitis C viral infection in a mammal by administering thereto an anti-hepatitis C virally effective amount of a compound of formula I according to one or more of the claims 1 to 24, or a pharmaceutically acceptable salt or ester thereof in combination with at least one other antiviral agent.
34. The method according to claim 33, wherein said antiviral agent is ribavirin.
35. The method according to claim 33, wherein said other antiviral agent is selected from another anti-HCV agent, HIV inhibitor, HAV inhibitor and HBV inhibitor.
36. The method according to claim 35, wherein said other anti-HCV agent is selected from immunomodulatory agents, other inhibitors of HCV NS3 protease, inhibitors of HCV polymerase and inhibitors of another target in the HCV life cycle.
37. The method according to claim 36, wherein said immunomodulatory agent is selected from α -interferon and pegylated α -interferon.
38. The method according to claim 36, wherein said inhibitor of another target in the HCV life cycle is selected from inhibitors of: helicase, NS2/3 protease and

internal ribosome entry site (IRES).

39. Use of a compound of formula I, including a pharmaceutically acceptable salt or ester thereof, according to one or more of the claims 1 to 24 for the manufacture of a medicament for the treatment or prevention of hepatitis C viral infection in a mammal.

SEQUENCE LISTING

<110> BOEHRINGER INGELHEIM INTERNATIONAL GmbH

<120> HEPATITIS C INHIBITOR TRI-PEPTIDES

<130> 13/113

<160> 3

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Forward primer

<400> 1

acgcagaaag cgtcttagcca tggcgtttagt

<210> 2

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Reverse primer

<400> 2

tcccggggca ctcgcaagca ccctatcagg

<210> 3

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> PUTR probe

<400> 3

tggtctgcgg aaccggtgag tacacc

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/CA2004/000318

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07K/08 A61K38/06 A61P31/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, WPI Data, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6 323 180 B1 (GOUDREAU NATHALIE ET AL) 27 November 2001 (2001-11-27) the whole document -----	1-39
A	WO 99/07733 A (BOEHRINGER INGELHEIM CA LTD ; RANCOURT JEAN (CA); SIMONEAU BRUNO (CA);) 18 February 1999 (1999-02-18) claims -----	1-39
X	WO 00/09543 A (BOEHRINGER INGELHEIM CA LTD ; GOUDREAU NATHALIE (CA); GHIRO ELISE (CA)) 24 February 2000 (2000-02-24) cited in the application Compounds 333, 334, 616, 621, 629, 630 in Tables 3 and 4, as well as in claims 52, 53, 58, 59claims 1,5,6,11,14-23,26,27,30,31,33-39,41,44,46, 47,66-71 ----- -/-	1-39

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

14 July 2004

Date of mailing of the international search report

22/07/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Döpfer, K-P

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA2004/000318

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00/09558 A (BOEHRINGER INGELHEIM CA LTD ; GOUDREAU NATHALIE (CA); GHIRO ELISE (CA)) 24 February 2000 (2000-02-24) the whole document -----	1-39

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2004/000318

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 32-38 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA2004/000318

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 6323180	B1	27-11-2001	US 6534523 B1 US 6268207 B1 US 6329379 B1 US 6329417 B1 US 2002016442 A1 US 2002037998 A1 AU 769738 B2 AU 5273199 A BG 105232 A BR 9913646 A CA 2338946 A1 CA 2445938 A1 WO 0009543 A2 CN 1323316 T CZ 20010516 A3 EA 3906 B1 EE 200100081 A EP 1105413 A2 HR 20010102 A1 HU 0105144 A2 ID 27839 A JP 2002522554 T NO 20010683 A NZ 510396 A PL 346626 A1 SK 2062001 A3 TR 200100432 T2 TR 200200129 T2	18-03-2003 31-07-2001 11-12-2001 11-12-2001 07-02-2002 28-03-2002 05-02-2004 06-03-2000 30-11-2001 05-06-2001 24-02-2000 24-02-2000 24-02-2000 21-11-2001 15-08-2001 30-10-2003 15-08-2002 13-06-2001 28-02-2002 29-04-2002 26-04-2001 23-07-2002 02-04-2001 27-02-2004 25-02-2002 08-10-2001 21-09-2001 21-06-2002

WO 9907733	A	18-02-1999	AU 757783 B2 AU 8795698 A CA 2294049 A1 WO 9907733 A2 EP 1003775 A2 HU 0004853 A2 JP 2001512743 T NZ 503262 A	06-03-2003 01-03-1999 18-02-1999 18-02-1999 31-05-2000 28-05-2001 28-08-2001 25-10-2002

WO 0009543	A	24-02-2000	AU 769738 B2 AU 5273199 A BG 105232 A BR 9913646 A CA 2338946 A1 CA 2445938 A1 WO 0009543 A2 CN 1323316 T CZ 20010516 A3 EA 3906 B1 EE 200100081 A EP 1105413 A2 HR 20010102 A1 HU 0105144 A2 ID 27839 A JP 2002522554 T NO 20010683 A NZ 510396 A PL 346626 A1 SK 2062001 A3	05-02-2004 06-03-2000 30-11-2001 05-06-2001 24-02-2000 24-02-2000 24-02-2000 21-11-2001 15-08-2001 30-10-2003 15-08-2002 13-06-2001 28-02-2002 29-04-2002 26-04-2001 23-07-2002 02-04-2001 27-02-2004 25-02-2002 08-10-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/CA2004/000318

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0009543	A	TR	200100432 T2	21-09-2001
		TR	200200129 T2	21-06-2002
		US	6534523 B1	18-03-2003
		US	6323180 B1	27-11-2001
		US	6268207 B1	31-07-2001
		US	6329379 B1	11-12-2001
		US	6329417 B1	11-12-2001
		US	2002016442 A1	07-02-2002
		US	2002037998 A1	28-03-2002
<hr/>				
WO 0009558	A 24-02-2000	AU	764655 B2	28-08-2003
		AU	5273299 A	06-03-2000
		BG	105230 A	31-10-2001
		BR	9912943 A	08-05-2001
		CA	2336597 A1	24-02-2000
		WO	0009558 A1	24-02-2000
		CN	1315965 T	03-10-2001
		EE	200100080 A	15-08-2002
		EP	1105422 A1	13-06-2001
		HR	20010101 A1	28-02-2002
		HU	0104548 A2	29-04-2002
		ID	27784 A	26-04-2001
		JP	2002522557 T	23-07-2002
		NO	20010604 A	05-02-2001
		NZ	510395 A	19-12-2003
		PL	346051 A1	14-01-2002
		TR	200100438 T2	21-06-2001
		ZA	200100972 A	18-07-2002
<hr/>				